(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 21 February 2002 (21.02.2002)

PCT

(10) International Publication Number WO 02/14482 A2

(51) International Patent Classification7: C12N 9/00

(21) International Application Number: PCT/GB01/03642

(22) International Filing Date: 14 August 2001 (14.08.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0019986.9

14 August 2000 (14.08.2000) Gl

(71) Applicant (for all designated States except US): BIOTICA TECHNOLOGY LIMITED [GB/GB]; 181A Huntingdon Road, Cambridge, Cambridgeshire CB3 0DJ (GB).


- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PETKOVIC,

Hrvoje [SI/GB]; 89 Argyle Street, Cambridge, Cambridgeshire CB1 3LS (GB). KENDREW, Steven, Gary [GB/GB]; 6 Cowper Road, Cambridge, Cambridgeshire CB1 3SN (GB). LEADLAY, Peter, Francis [GB/GB]; 6 Westberry Court, Pinehurst, Grange Road, Cambridge, Cambridgeshire CB3 9BG (GB).

- (74) Agents: STUART, Ian et al.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,

[Continued on next page]

(54) Title: POLYKETIDES AND THEIR SYNTHESIS



(57) Abstract: Biosyntheses of compounds whereof at least portions are polyketides produced by means of polyketide synthase (PKS) enzyme complexes are carried out after specific alterations have been made within the acyltransferase (AT) domains of the PKSs. Particular motifs in or near the substrate binding pocket are disclosed, such that alterations therein affect substrate specificity.

WO 02/14482 A2



(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

1

Polyketides and Their Synthesis

Technical Field

5

10

15

20

25

The present invention relates to processes and materials (including enzyme systems, nucleic acids, vectors and cultures) which can be used to influence the selection of acylthioester units for the synthesis of polyketides, and to the resulting polyketides, which may be novel. It is particularly concerned with macrolides, polyethers or polyenes and their preparation making use of recombinant synthesis.

In preferred types of embodiment, polyketide biosynthetic genes or portions of them, which may be derived from different polyketide biosynthetic gene clusters, are manipulated to allow the production of specific polyketides, such as 12-, 14- and 16-membered macrolides, of predicted structure. The invention is particularly concerned with the modification of an Acyl CoA:ACP transferase (AT) function, generally by modifying genetic material encoding it in order to prepare polyketides with a predetermined ketide unit, e.g. incorporating (a) a malonate extender unit; or (b) a methylmalonate extender unit; or (c) an ethylmalonate extender unit; or (d) a further type of extender unit; or (e) an acetate and/or malonate starter unit; or (f) a

2

propionate and/or methylmalonate starter unit; or (g) a butyrate and/or ethylmalonate starter unit; or (h) a further type of starter unit. Of course the invention can be used to influence more than one ketide unit of a polyketide. The method enables one to minimise alteration to the protein structure of the polyketide synthase.

10

15

20

25

Polyketides are a large and structurally diverse class of natural products that includes many compounds possessing antibiotic or other pharmacological properties, such as erythromycin, tetracyclines, rapamycin, avermectin, monensin, epothilone and FK506. In particular, polyketides are abundantly produced by Streptomyces and related actinomycete bacteria. synthesised by the repeated stepwise condensation of acvlthioesters in a manner analogous to that of fatty acid biosynthesis. The structural diversity found among natural polyketides arises in part from the selection of (usually) acetate (malonyl-CoA) or propionate (methylmalonyl-CoA) as "starter" or "extender" units (although one of a variety of other types of unit may occasionally be selected); as well as from the differing degree of processing of the β -keto group formed after each condensation. Examples of processing steps include reduction to β -hydroxyacyl-, reduction followed by

3

dehydration to 2-enoyl-, and complete reduction to the saturated acylthioester. The stereochemical outcome of these processing steps is also specified for each cycle of chain extension. Methylation at the α -carbon or β -hydroxy is also sometimes observed.

10

15

20

The biosynthesis of polyketides is performed by a group of chain-forming enzymes known as polyketide synthases. Two broad classes of polyketide synthase (PKS) have been described in actinomycetes. One class, named Type I PKSs, represented by the PKSs for the macrolides erythromycin, oleandomycin, avermectin, and rapamycin and by the PKS for the polyether monensin, consists of a different set or "module" of enzymes for each cycle of polyketide chain extension. For an example see Figure 1 (Cortés, J. et al. Nature (1990) 348:176-178; Donadio, S. et al. Science (1991) 2523:675-679; Swan, D.G. et al. Mol. Gen. Genet. (1994) 242:358-362; MacNeil, D. J. et al. Gene (1992) 115:119-125; Schwecke, T. et al. Proc. Natl. Acad. Sci. USA (1995) 92:7839-7843; also Patent application W098/01546). The genes encoding numerous Type I PKSs have been sequenced and these sequences disclosed in publicly available DNA and protein sequence databases including Genbank, Swissprot and EMBL. For example, the sequences are available for the PKSs

4

governing the synthesis of erythromycin (Cortes, J. et al. Nature (1990) 348:176-178); accession number X62569, Donadio, S. et al. Science (1991) 252:675-679; accession number M63677); rapamycin (Schwecke, T. et al. Proc. Natl. Acad. Sci. (1995) 92:7839-7843; accession number

X86780); rifamycin (August, P.et al. Chem. Biol. (1998) 5:69-79; accession number AF040570) and tylosin (Eli Lilly, accession number U78289), among many others.

10

15

20

The term "polyketide synthase" (PKS) as used herein refers to a complex of enzyme activities responsible for the biosynthesis of polyketides. These enzyme activities include β -ketoacyl ACP synthase (KS), acyltransferase (AT), acyl carrier protein (ACP), β -ketoreductase (KR), dehydratase (DH), enoylreductase (ER) and thioesterase (TE) but are not limited to these activities. Each of these activities lies on a separate protein or polypeptide fragment responsible for this activity. Such a fragment is termed a "domain". The terms "motif" or "signature sequence" used herein refer to a small stretch of amino acids (usually less than 10 amino acids) within a domain responsible (at least in part) for one aspect of the catalytic function, for example, choice of substrate. The term "extension module" as used herein refers to the set of contiquous domains, from a β-ketoacyl-ACP synthase

5

("KS") domain to the next acyl carrier protein ("ACP") domain, which accomplishes one cycle of polyketide chain extension; this may or may not include domains responsible for the reductive processing of the polyketide chain. The term "loading module" is used to refer to any group of contiguous domains that accomplishes the loading of the starter unit onto the PKS and thus renders it available to the KS domain of a specific extension module.

10

15

20

25

5

Background Art

Several approaches to altering the nature of the polyketide product of a PKS by genetic engineering have been proposed: see particularly WO 93/13663 and WO 98/01571. The length of polyketide formed has been altered, in the case of erythromycin biosynthesis, by specific relocation using genetic engineering of the enzymatic domain of the erythromycin-producing PKS that contains the chain-releasing thioesterase/cyclase activity (Cortés, J.et al. Science (1995) 268:1487-1489; Kao, C.M. et al. J. Am. Chem. Soc. (1995) 117:9105-9106).

In-frame deletion of the DNA encoding part of the ketoreductase domain in module 5 of the erythromycin-producing PKS (also known as 6-deoxyerythronolide B synthase, DEBS) has been shown to lead to the formation

6

of erythromycin analogues 5,6-dideoxy-3-α-mycarosyl-5oxoerythronolide B, 5,6-dideoxy-5-oxoerythronolide B and
5,6-dideoxy, 6 β-epoxy-5-oxoerythronolide B (Donadio, S.
et al. Science (1991) 252:675-679). Likewise, alteration
of active site residues in the encylreductase domain of
module 4 in DEBS, by genetic engineering of the
corresponding PKS-encoding DNA and its introduction into
Saccharopolyspora erythraea, led to the production of
6,7-anhydroerythromycin C (Donadio, S. et al. Proc Natl.

Acad. Sci. USA (1993) 90:7119-7123).

Patent application WO 00/01827 describes further methods of manipulating a PKS to change the oxidation state of the β -carbon. Substituting the reductive domain of module 2 of the erythromycin-producing PKS with domains derived from rapamycin PKS modules 10 and 13 led to the formation of C10-C11 olefin-erythromycin A and C10-C11 dihydroerythromycin A respectively.

15

20

The second class of PKS, named Type II PKSs, is represented by the synthases for aromatic compounds.

Type II PKSs contain only a single set of enzymatic activities for chain extension and these are re-used as appropriate in successive cycles (Bibb, M. J. et al. EMBO J. (1989) 8:2727-2736; Sherman, D. H. et al. EMBO J. (1989) 8:2717-2725; Fernandez-Moreno, M.A. et al. J.

7

Biol. Chem. (1992) 267:19278-19290). The "extender" units for the Type II PKSs are usually acetate (malonyl-COA) units, and the presence of specific cyclases dictates the preferred pathway for cyclisation of the completed chain into an aromatic product (Hutchinson, C. R. and Fujii, I. Annu. Rev. Microbiol. (1995) 49:201-238). Hybrid polyketides have been obtained by the introduction of cloned Type II PKS gene-containing DNA into another strain containing a different Type II PKS 10 gene cluster, for example by introduction of DNA derived from the gene cluster for actinorhodin, a blue-pigmented polyketide from Streptomyces coelicolor, into an anthraquinone polyketide-producing strain of Streptomyces galileus (Bartel, P. L. et al. J. Bacteriol. (1990) 15 172:4816-4826). Occasionally, unusual starter units are incorporated by Type II PKS, particularly in the biosynthesis of oxytetracycline, frenolicin and daunorubicin and in these cases a separate AT is used to transfer the starter unit to the PKS.

Fungal PKSs such as the 6-methylsalicylic acid or lovastatin PKS typically consist of a single multi-domain polypeptide which include most of the activities required for the synthesis of the polyketide portion of these molecules (Hutchinson C.R. and Fujii I. Annu. Rev.

25 Microbiol. (1995) 49:201-238). Type II Fungal PKSs are

8

also known.

10

15

20

25

A number of mixed systems comprising polyketide synthase and nonribosomal peptide synthase modules have been identified including the epothilone and bleomycin biosynthetic clusters.

Although large numbers of therapeutically important polyketides have been identified, there remains a need to obtain novel polyketides that have enhanced properties or possess completely novel bioactivity. The complex polyketides produced by Type I PKSs are particularly valuable, in that they include compounds with known utility as anthelminthics, insecticides, anticancer, immunosuppressants, antifungal or antibacterial agents. Because of their structural complexity, such novel polyketides are not readily obtainable by total chemical synthesis, or by chemical modifications of known polyketides. Particular changes that are desired are changes to the carbon skeleton by altering the nature of the starter and/or extender unit(s) incorporated, changes to the oxidation level of the β -keto carbon and therefore the pattern of oxygen substituents by altering the series of reductive steps that occur after chain extension and changes to the post PKS "tailoring" steps which generally comprise hydroxylation, methylation or glycosylation of the polyketide molecule.

There is also a need to develop reliable and specific ways of deploying individual modules in practice so that all, or a large fraction, of hybrid PKS genes that are constructed, are viable and produce the desired polyketide product. Various strategies have been described to produce these hybrid PKSs particularly utilising recombinant DNA technology and denovo biosynthesis. There is a particular need to develop methods of manipulating these PKS in a manner that minimises the alteration to the PKS protein structure. Existing methods of achieving these manipulations sometimes produce hybrid PKS multienzymes which give the desired product at only 1% or less of the rate that the unmodified PKS produces product.

WO 93/13663 and WO 98/01571 describe novel methods of engineering PKSs. A well-established method of altering the nature of the extender unit used at any position in the polyketide molecule, particularly malonyl-, methylmalonyl- or ethylmalonyl-CoA is by domain substitution. For example, WO98/01546 and US patent 6,063,561 disclose methods of accomplishing this modification to form modified erythromycins. Novel polyketide molecules, in this case particularly novel erythromycins, are produced by the replacement of an entire AT domain-encoding DNA fragment on the

10

Saccharopolyspora erythraea chromosome with an equivalent heterologous AT domain-encoding fragment from another PKS cluster. It is well known to those skilled in the art that selection of the exact DNA/protein splice sites into which to insert the heterologous domain requires detailed analysis of the corresponding DNA and protein sequences. Different researchers choose to use splice sites at conserved, semi-conserved or non-conserved regions of the protein, or at sites either within or at the boundaries of the AT domains. A further drawback of this technique is that it is hard to predict whether a particular heterologous domain will work in any given context. A domain that works successfully in one module may not work at all in an adjoining module or may produce polyketides at a vastly reduced yield. Oliynyk, M. et al. (Chem. Biol. (1996) 3:833-839) and Ruan et al. (J. Bact. (1997) 179:6416-6425) have published studies that exchange a methylmalonyl-CoA specific AT domain for malonyl-CoA specific AT domains in modules of the erythromycin PKS. Products were observed only for changes in modules 1 and 2, with module 2 at a vastly lowered yield. Stassi et al. (Proc. Natl. Acad. Sci. (1998) 95:7305-9) exchange the methylmalonyl-CoA specific AT of module 4 of the erythromycin PKS for an ethylmalonyl-CoA specific AT and

10

15

20

11

again product yield was low even after the addition of the crotonyl-CoA reductase gene thought to increase the supply of the required ethylmalonyl-CoA precursor. A possible reason for the limiting yields is the structural or mechanistic non-compatibility of a heterologous AT domain with the adjoining KS and ACP domains with which it must interact properly for efficient polyketide chain synthesis. Consequently, it is often necessary to try multiple domain swaps to achieve a novel polyketideproducing strain that displays adequate efficiency - a process made particularly arduous when these changes must be made by gene replacement on the chromosome through a two step double integration process. The introduction of splice sites at the DNA level is time consuming and technically challenging, requiring careful analysis to ensure the PKS protein coding reading frame is not disrupted. The introduction of restriction enzyme sites often requires changes at the amino acid level which lead to further PKS protein structure disruption and consequent loss of catalytic efficiency.

5

10

15

20

25

A method that could utilise the numerous techniques available for site directed mutagenesis to influence the AT substrate specificity with minimal disruption to the protein tertiary structure would be a valuable addition to the current techniques.

Changes to an active site have been shown to alter substrate specificity in other systems. For example, in an early study, Scrutton et al. (Nature (1990) 343:38-43) used site directed mutagenesis to switch the coenzyme substrate specificity of a glutathione reductase. Identifying and changing a 'fingerprint' structural motif in the NADP+ binding domain they could convert the enzyme into one displaying a marked preference for NAD+. The techniques of directed evolution have been used to improve/change enzyme catalytic function. Of many examples in the literature, Zhang et al. (PNAS (1997) 94:4504-4509) illustrate the conversion of a galactosidase to a fucosidase by these techniques. The resulting protein bears 6 mutations, of which 3 lie in, or in close proximity to the active site.

Minor but directed changes to a PKS domain can make significant changes to its catalytic function. Patent application WO 00/00500 teaches that an extender ketosynthase domain is converted to a decarboxylating (and hence loading) ketosynthase domain by site directed mutagenesis at the active site. US Patent numbers 6,004,787 and 6,066,721 and Jacobsen et al. Science (1997)277:367-369 describe the deletion of residues in the KS1 active site to inactivate this activity to allow the production of novel polyketides by feeding of

13

synthetic precursors to the modified PKS.

5

10

15

20

Several studies have attempted to correlate the primary amino acid sequence of the AT to determine amino acids directly involved with the recognition of the appropriate substrate, and particularly the nature of the substrate side chain (i.e. the malonyl portion of the acyl-CoA thioester). Studies by Haydock et al. (FEBS Lett. (1995) 374:246-248) correlated the substrate specificity of malonyl- or methylmalonyl-CoA specific AT with a motif 11 amino acids upstream of the known active site. Comparisons between this motif and the protein structure of a known acyltransferase from E. coli fatty acid synthase allowed the authors to assess the proximity of the motif residues to the active site (and hence its ability to select the substrate). The authors acknowledged that "this divergent region thus identified lies near the acyltransferase active site though not close enough to make direct contact with the substrate". Other studies (Katz, L. Chem Rev. (1997) 97:2557-2575, Tang, L. et al., Gene (1998) 216:255-265) have correlated additional residues with a specific extender unit using these residues as a tool to predict the AT substrate specificity from a protein sequence derived from polyketide gene cluster sequencing projects. It has

14

remained unclear which residues have mechanistic importance. In only one case have regions within the PKS AT domain been exchanged in an attempt to swap AT specificity; patent application WO 00/01838 and Lau et al. Biochemistry (1999) 38:1643-51) implicated a 'hypervariable region' at the C-terminus of the AT domain in the selection of extender unit. These workers interchanged this 25-30 amino acid stretch and showed that this change was sufficient to alter the substrate specificity of the AT, concluding "a short (23-35 amino 10 acid) C-terminal segment present in all AT domains is the principal determinant of their substrate specificity. Interestingly its length and amino acid sequence vary considerably among the known AT domains. We therefore suggest that the choice of extender units by the PKS 15 modules is influenced by a "hypervariable region", which could be manipulated via combinatorial mutagenesis to generate novel AT domains possessing relaxed or altered substrate specificity". Surprisingly, our structure molecular modelling studies indicate this region lies at 20 a surface accessible region away from the active site and hence is unlikely to directly interact with (and hence directly select) the malonyl portion or the substrate

15

used. The effect on substrate specificity is therefore likely to be imprecise and due to more indirect effects via, for example, disruption of tertiary structure.

5 <u>Disclosure of Invention</u>

10

15

20

25

According to a first aspect of the present invention there is provided a method of synthesising a compound whereof at least a portion is the product of a polyketide synthase (PKS) enzyme complex or is derived from such a product, said PKS enzyme complex including at least one acyltransferase (AT) domain. The method includes a step of providing said PKS enzyme complex in which said AT domain has been altered to change selectively a minor proportion of amino acid residues. The altered residue(s) may comprise one or more motifs which are present in the active site pocket of the AT domain and which influence the substrate specificity of the AT domain, the alteration affecting the substrate specificity; and/or one or more residues of a motif which influences the substrate specificity of the AT domain and which comprises a four-residue sequence corresponding to the YASH motif of the AT domain of the first module of DEBS, the alteration affecting the substrate specificity. Synthesis is then effected by means of said PKS enzyme complex to produce a compound or mixture of compounds

16

different from what could have been produced by means of a PKS enzyme in which said AT domain had not been altered.

The PKS enzyme complex may be at least part of a modular type I PKS enzyme complex, or it may be derived from a type II PKS system, a fungal PKS system or a hybrid system comprising PKS and nonribosomal peptide synthase modules.

5

10

15

20

25

The present invention teaches that by altering a few amino acid residues in the AT domain and particularly residues close to the AT active site comprising one or more residues of a short signature "motif" within the AT domain it is possible to influence the acylthioester selected by that AT domain. Novel polyketides can be made by a modified PKS on which the signature motif on one or more modules is altered, e.g. being replaced with one associated with a different specificity for malonyl substrate. Furthermore, the invention provides a method of reducing the proportion of mixed polyketide products that are occasionally found in natural systems due to non-specific incorporation of the incorrect extender units. Conversely, the invention provides a method of giving a mixed population of polyketide products thus increasing the diversity of polyketides produced by a PKS.

17

The invention allows the preparation of a modified PKS by substitution of an existing amino acid residue motif in the AT that specifies incorporation of one of the common extender acylthioesters with another motif found in another AT specifying an alternative acylthioester. This alters the substrate specificity of the polyketide synthase when it is expressed in a polyketide-producing organism.

5

20

25

The DNA sequences have been disclosed for numerous

Type I PKS gene clusters. Comprehensive sequence
analysis of AT domains derived from Type I PKS modules
responsible for the formation of macrolides, particularly
erythromycin, rapamycin, avermectin, rifamycin, FK506,
epothilone, tylosin, and niddamycin, ionophore

polyethers, particularly monensin, and polyenes,
particularly nystatin, allowed us to identify amino acids
that are characteristic of AT domains.

Figure 2 shows the sequence comparison of these AT domains. This sequence comparison has been generated in a generally conventional way, employing a computer using a procedure that creates a multiple sequence alignment from a group of related sequences. We used a program called PileUp (Wisconsin Package, Genetics Computer Group (GCG), Madison, WI,USA), which creates a multiple sequence alignment using simplification of the

18

progressive alignment method of Feng and Doolittle (Journal of Molecular Evolution 25; 351-360 (1987)). method used is similar to the method described by Higgins and Sharp (CABIOS 5; 151-153 (1989)). The program executes a series of progressive, pairwise alignments that allows a large number of sequences to be compared together to form a final alignment throughout all the sequences. Gaps can be inserted throughout individual sequences to allow alignment of regions of strong similarity. This is often required as strongly conserved regions are often separated by more variable regions, both in terms of numbers of amino acids and type of amino acids. Different programs use different mathematical algorithms to make these comparisons, resulting in alignments that differ in minor ways. However, it can be expected that regions of strong homology would still align whatever alignment program is utilised. particular motifs that are discussed are marked.

10

15

20

25

These motifs include the conserved GQG motif that is close to the start of the domain, the GHS motif that contains the active site serine that covalently binds the acyl chain prior to transfer to the ACP, and a LPTY motif that is close to the end of the domain. Other residues common to all ATs including an arginine, believed to stabilise the carboxylate group of the acylthicester.

19

Further detailed sequence analysis allowed us to identify amino acid residues that differed between ATs responsible for the incorporation of malonyl-, methylmalonyl- and ethylmalonyl-CoA. Some of these amino acids or motifs had been previously identified during the sequence 5 analysis of the clusters as previously discussed. While these motifs could predict whether a malonyl-/methylmalonyl-CoA might be used they generally fail to show a difference between methylmalonyl- vs ethylmalonyl-CoA or the other larger extender unit commonly used. We 10 viewed this as an important requirement for identification of the most important and key residues involved in substrate recognition and consequently residues most suitable for alteration. Closer analysis identified a string of four residues (location identified 15 clearly in Figure 2) of which two residues are virtually invariant throughout all ATs, and two residues differ consistently depending on the extender unit. Particularly, in the vast majority of ATs responsible for recognition of malonyl-CoA the sequence of residues HAFH 20 was identified. In the majority of ATs responsible for recognition of methylmalonyl-CoA the equivalent segment was substituted by residues YASH. In ATs responsible for ethylmalonyl-CoA or other similar sized CoA unit incorporation the overall motif was different, less 25

ţ

5

10

15

20

20

conserved but generally displayed the sequence XAGH

(where X is most frequently but not limited to F, T, V or

H). We typically use the terms HAFH, YASH and TAGH to

describe these motifs with respect to malonyl-CoA,

methylmalonyl-CoA and ethylmalonyl/further CoA

specificity but use these terms herein to allow

substitutions in the motif, particularly at residue 1 as

described. Potential substitutions and the exact

location of the motif will be clear to those skilled in

the art by inspection of Figure 2 or similar sequence

analysis.

There are three possible methods to locate the position of the motif within an AT sequence that does not appear in Figure 2. It is likely a combination of the methods will be used.

- I) By simple visual inspection and comparison of the sequence to identify the motifs HAFH, YASH or TAGH. Since substitutions of residue one are often encountered a useful procedure is to look for an alanine (A) separated by one amino acid (usually F, S or G) from a histidine (H).
- II) By counting amino acids from the active site serine. The start of the motif is typically (but should not be limited to) between 90 and

21

100 amino acids downstream of the GHS active site motif.

III) By computer generated multiple alignment that allows the new sequence to be directly compared to the sequences and motifs we have annotated in Figure 2 or to other ATs.

5

10

15

20

25

It is preferable to use the third method as this allows the motif to be identified unequivocally when there are substitutions within the motif. This is particularly necessary in some of the more unusual types of AT in which one of the residues can be substituted by proline (P). The third method will also identify the motif when the number of residues between the motif and the AT active site serine differs significantly from the norm. The third method will also better identify the motif when the same or similar string of amino acids occurs elsewhere in the domain.

A particular feature of these motif residues is the relationship of the size of the third residue compared to the substrate selected. Hence, when malonyl-CoA is required the third residue is large (phenylalanine), when methylmalonyl-CoA is required this residue is intermediate (serine), and when ethylmalonyl-CoA is required this residue is small (glycine). The inverse relationship between substrate side chain size and this

22

third residue is particularly noteworthy. Interestingly, this relationship applies also when considering the incorporation of the more unusual extender units such as methoxymalonyl-CoA, required for some cycles of chain extension during production of for example FK506 (HAGH). Currently, only a single example of an AT responsible for the incorporation of a five carbon-CoA unit has been disclosed. In this case the AT displays a different motif at this point, CPTH, in which only the histidine is conserved. The incorporation of a proline residue in the motif may be indicative of an AT specifying a larger substrate. Proline is also found in the motif in ATs that incorporate the larger unusual starter acids as seen in the case of avermectin and soraphen. Residues in and around this area, but lying in the active site of the AT domain define the specificity of the domain towards the substrate chosen.

10

15

20

25

Motifs that represent hybrids of motifs for malonyland methylmalonyl-CoA or methylmalonyl- and ethylmalonylCoA were identified. Particularly, epothilone module 3expected HAFH or YASH (malonyl-CoA or methylmalonyl-CoA
specific), found HASH or monensin module 5-expected TAGH
(ethylmalonyl-CoA specific), found VAGH. Significantly,
in both these cases the products of the PKS are a mixture
due to the incorporation of 2 different extender units by

23

the module containing the hybrid motif, causing formation of monensins A and B and epothilones A and B. However, it is known that substrate supply is a significant determinant of the proportion of monensins A and B formed (Liu, H. and Reynolds, K.A (1999) J. Bact. 181:6806-6813).

Many of the previously-proposed "predictive" motifs are unlikely to be the principal determinant of substrate specificity because they are not located in the active site pocket. A particular requirement of any motif that can serve to distinguish between substrates is that it lies close to the active site and preferably within the substrate binding pocket. In this analysis we consider the substrate binding pocket to be the part of the pocket that binds/recognises the malonyl portion of the acylthioester rather than necessarily the coenzyme A portion. In all probability some of the similarities previously identified by sequence analysis are due to evolutionary conservation rather than a mechanistic requirement. In contrast the residues we have identified lie in or close to the substrate binding pocket. To assess the exact location of the motif in space we compared the protein sequence of ATs derived from Type I PKS with that of E. coli fatty acid malonyl-CoA:ACP acyltransferase, for which there is a high resolution X-

10

15

20

25

ray crystal structure (Serre, L. et al., J. Biol. Chem. (1995) 270:12961-12964). While overall level of sequence similarity between these proteins is low, key residues (and particularly those with mechanistic importance) are conserved and the overall spatial arrangement of amino acids is expected to be conserved. Many groups have used this structure as a model AT and it is well known in the art that conservation of structure can be greater than the level of sequence conservation. Structural analysis showed that the identified motif would lie within the active site pocket opposite the active site serine and the arginine thought to be involved in binding the substrate carboxylate and close enough to the acyltransferase site to interact with the bound substrate side chain. The invariant histidine found in the motif is thought be part of a catalytic triad with the active site serine as is typically found in serine hydrolases (Serre et al, Supra). Figure 3 shows the position of the motif loop and important active site residues in the model AT structure.

5

10

15

20

Broadly the invention concerns modifying an AT domain by changing the four-residue sequence or motif responsible for selecting a substrate so that its specificity is altered. We may also change a small number of other residues close to the active site.

25

Generally the total number of residues changed is less than 5% of the residues of the AT.

The motif is the four-residue sequence corresponding to the YASH motif found at about residues 334-337 of the AT domain of the first module of DEBS, numbering as shown in Fig. 2. It lies in the active site pocket. It typically starts 80-110, more particularly 90-100, amino acids downstream of the GHS active site motif.

In a preferred embodiment of this invention polyketides of desired structure are 'produced by the 10 replacement of an existing AT motif on a PKS with an alternative one responsible for selection of an alternative extender or starter unit, or responsible for an altered degree of selectivity (in most cases, increased selectivity). This may be carried out in one 15 or more of the modules encoding a PKS cluster. One type of embodiment is a PKS including two adjoining domains, which are "naturally" adjoining or otherwise coupled domains, wherein the first of them is an AT domain where the four-residue motif has been altered to change its 20 specificity, the AT domain acting to transfer a substrate to the second domain.

In one class of embodiments, this invention provides a PKS multienzyme or part thereof, or nucleic acid (generally DNA) encoding it, said multienzyme or part

25

26

comprising a loading module and a plurality of extension modules for the generation of a polyketide, preferably selected from, macrolides, polyethers, or polyenes, wherein the loading or extension modules or at least one thereof contain a modified AT domain adapted to load and transfer an optionally substituted malonyl-CoA residue to (preferably) the ACP. The AT domain is preferably modified to alter its substrate specificity. This AT domain may differ from one naturally found in this position in the module only by the modification of a few amino acids lying in the active site. This modification comprises the exchange of all or part of a motif particularly but not limited to HAFH with YASH or TAGH or vice versa. Optionally, alterations to amino acids outside this sequence, but preferably lying close to the AT active site, are made.

5

10

15

20

25

A second class of embodiments provides a method of synthesising polyketides having a desired extension unit at any point around the polyketide molecule by providing a PKS multienzyme incorporating one or more modified AT domains and particularly but not limited to an AT domain possessing the motif HAFH or YASH or TAGH where these motifs replace the existing natural motif. Optionally, alterations to amino acids outside this sequence, but preferably lying close to the AT active site, are made.

27

A third class of embodiments provides a method of synthesising polyketides having a desired starter unit by providing a PKS multienzyme incorporating a modified AT domain in the loading module and particularly (but not limited to) an AT domain possessing the motif HAFH or YASH or TAGH or a motif incorporating a proline residue where these motifs replace the existing natural motif. Optionally, alterations to amino acids outside this sequence, but preferably lying close to the AT active site, are made. Preferentially, this AT will follow a KSQ domain but other loading systems are known in the art (e.g. AT-ACP). Patent application WO 00/00500 describes some of the known loading systems. The modification of the loading module can be combined with similar modifications in other extension units.

5

10

15

20

25

A further class of embodiments provides a method of synthesising polyketides free of natural co-produced analogues and having a desired extender or loading unit by replacing an existing hybrid or alternative protein motif with the sequences HAFH, YASH or TAGH. It is particularly useful to make this alteration in the epothilone or monensin PKS gene cluster.

In still further aspects this invention provides a method of synthesising a mixed population of polyketides by providing a PKS multienzyme incorporating an AT with a

28

altered or hybrid motif, particularly, but not limited to HASH or VAGH. One particular utility of this method, though not limited to this utility, is the production of combinatorial libraries of compounds.

5

10

15

20

25

In a further aspect the PKS containing a modified AT domain may be spliced to a hybrid PKS produced for example as in WO 98/01546 and WO 98/01571 or WO 00/01827 or WO 00/00500. It is particularly useful to link such a modified PKS to gene assemblies that produce novel derivatives of natural polyketides, for example 14-membered macrolides.

Each of these aspects and classes of embodiment may involve providing nucleic acid encoding the polyketide synthase multienzyme and introducing it into a organism where it can be expressed. Suitable plasmids and host cells are described below. The polyketide synthase so produced or portions thereof may be isolated from the host cells by routine methods, though it is usually preferable not to do so. The host cells may also be capable of producing the required acylthioester, eg. by producing ethylmalonyl CoA for example. It may be advantageous to remove the PKS from a strain with a particularly strong supply of an undesired acylthioester or express the altered PKS in a strain specifically chosen to have a strong supply of a particular

acylthioester, or alternatively to develop media or growth conditions to enhance expression of the desired product. Conversely, such techniques could be used to promote formation of mixtures of products if so desired. It may also be beneficial to supply chemical precursors to the desired acylthioesters in the media e.g. supply diethylethylmalonate or cyclobutane carboxylic acid etc. The host cells may also be capable of modifying the initial PKS products, e.g. by carrying out all or some of the biosynthetic modifications normal in the production of erythromycin (as shown in figure 4) and for other polyketides. Use may be made of mutant organisms such that some or all of the normal pathways are blocked, e.g. to produce products without one or more "natural" hydroxy groups or methyl groups or sugar groups.

The invention should not be limited to the exact motifs described. We have described some of the known variations within the motif, particularly at residue 1 as can be determined by inspection of Figure 2 or by inspection of similar sequence data. However other modifications can be envisaged; substitution of, for example, the phenylalanine in the malonyl-CoA motif by the similar sized tyrosine may still display the same selectivity. Similarly substitution of the small residue glycine found in the motif responsible for ethylmalonyl-

30

CoA/other extender incorporation by for example but not limited to alanine. It is well known to those skilled in the art that these and other similar conservative substitutions frequently maintain the same selectivity. Similarly the serine residue found in the motif for incorporation of methylmalonyl-CoA could be substituted by a residue intermediate in size and/or displaying a similar charge distribution.

The invention should not be limited to changes only in this motif. Alterations to other residues around the AT domain may also be required to increase the level of specificity or catalytic efficiency, i.e. to increase the proportion or amounts of the desired products. These residues are preferentially close to the substrate binding pocket. The requirement for these additional alterations will depend on the particular context or change desired. Particular residues to alter can be readily identified by inspection of Figure 2 or other similar sequence analysis data or alternatively by analysis of the structural model.

10

15

20

25

Residues that may be altered in addition to the motif can be divided into two classes. Some of these residues may have been previously identified in the motifs used to predict the specificity of a motif (ie. Haydock et al. (FEBS Lett. (1995) 374:246-248). These

31

residues are preferentially close to the substratebinding pocket. These residues should not be limited to the particular examples described.

5

10

15

20

25

- I) The first class of potential residues to change includes residues close to the motif on the polypeptide chain. A particular example is the residue immediately after the 4 residue motif described in the present invention. In malonyl-CoA specific ATs this residue is generally serine (S), i.e. the protein sequence at this point is generally HAFHS, whereas in methylmalonyl-CoA specific ATs this residue can be S but can also be T, G, or C for example. Thus to change a methylmalonyl-CoA specific AT to a malonyl-CoA specific AT by changing the signature motif it may be beneficial also to ensure that the residue immediately after the motif is an S. Since this residue is close to the motif on the polypeptide chain it lies close to the substrate binding pocket.
- II) The second class includes residues that are close to the motif or active site in space. These residues are best identified by reference to the model AT structure described previously or another AT structure that may be subsequently derived. It is known to those skilled in the art that it is possible to thread related protein sequences into an existing structure by using structure molecular modelling or related techniques.

32

Alternatively, an acylthioester may be modelled into the active site. These are the preferred methods, but oftensimple inspection of the existing structure using the highly conserved motifs as a reference point gives a reasonable approximation.

A particular example of a residue close in space to the motif that might be changed is the residue immediately after the GHS active site motif. In methylmalonyl-CoA specific ATs this residue is generally glutamine (Q), i.e. the protein sequence at this point is GHSQ, whereas in malonyl-CoA specific ATs this residue is often V, I or L for example. Thus to change a malonyl-CoA specific AT to a methylmalonyl-CoA specific AT by changing the signature motif it may be beneficial also to ensure that the residue immediately after the GHS motif is a Q. Since this residue is close to the active site serine it lies within the substrate-binding pocket.

10

15

20

25

A further example of a residue close in space that might be altered is the residue lying three residues downstream of the GQG motif. In methylmalonyl-CoA specific ATs this residue is generally tryptophan (W), i.e. the protein sequence at this point is GQGXXW, whereas in malonyl-CoA specific ATs this residue is often R, H or T for example. Thus to change a malonyl-CoA specific AT to a methylmalonyl-CoA specific AT by

33

changing the signature motif it may be beneficial also to ensure that this particular residue after the GQG motif is a W. Analysis of the model AT structure shows that the GQG motif lies close to the active site pocket and consequently so does this tryptophan.

A further example of a residue close in space that might be altered is the residue 4 residues downstream from the conserved arginine referred to above, which is believed to stabilise the carboxylate group of the acylthioester substrate. In malonyl-CoA specific ATs this residue downstream of the R is generally methionine (M), i.e. the protein sequence at this point is RXXXMQ. In methylmalonyl-CoA specific ATs this residue is generally I or L, and in ethylmalonyl-CoA specific ATs it is often W. Thus, for example, to change a methylmalonyl-CoA specific AT to a malonyl-CoA specific AT by changing the signature motif it may be beneficial also to ensure that this particular residue is a methionine. Analysis of the model AT structure shows that this residue lies close to the active site pocket.

10

15

20

25

In further aspects the present invention provides vectors, such as plasmids or phages (preferably plasmids), including nucleic acids as defined in the above aspects and host cells particularly Saccharopolyspora or Streptomyces species transformed

5

10

15

20

34

with such nucleic acids or constructs. It will be readily apparent to those skilled in the art that there are multiple molecular biological methods for achieving the desired alterations to the AT domain, particularly at the nucleic acid level, e.g. techniques of site directed mutagenesis or directed evolution. Suitable plasmid vectors and genetically engineered cells suitable for expression of PKS genes with modules incorporating an altered AT domain can readily be designed or selected by those skilled in the art. They include those described in WO 98/01546 as being suitable for expression of hybrid PKS genes of Type I. Examples of effective hosts are Saccharopolyspora erythraea, Streptomyces coelicolor, Streptomyces avermitilis, Streptomyces griseofuscus, Streptomyces cinnamonensis, Streptomyces fradiae, Streptomyces longisporoflavus, Streptomyces hygroscopicus, Micromonospora griseorubida, Streptomyces lasaliensis, Streptomyces venezuelae, Streptomyces antibioticus, Streptomyces lividans, Streptomyces rimosus, Streptomyces albus, Amycolatopsis mediterranei, and Streptomyces tsukubaensis. These include hosts in which SCP2*-derived plasmids are known to replicate autonomously, such as for example S. coelicolor, S.

35

avermitilis and S. griseofuscus; and other hosts such as Saccharopolyspora erythraea in which SCP2*-derived plasmids become integrated into the chromosome through homologous recombination between sequences on the plasmid insert and on the chromosome; and all such vectors which are integratively transformed by suicide plasmid vectors. A plasmid with an int sequence will integrate into a specific attachment site on the host's chromosome.

5

10

15

20

It is apparent to those skilled in the art that the overall sequence similarity between nucleic acids encoding comparable AT domains from Type I PKSs is sufficiently high and the domain organisation of different Type I PKSs so consistent between different polyketide-producing organisms, that the processes for obtaining novel hybrid polyketides described will be generally applicable to all natural modular Type I PKSs or their derivatives.

The present invention will now be illustrated, but is not intended to be limited, by means of some examples.

Amino acids have been defined throughout by their standard one letter codes as follows. A-alanine, R-arginine, N-asparagine, D-aspartic acid, C-cysteine, Q-glutamine, E-glutamic acid, G-glycine, H-histidine, I-isoleucine, L-leucine, K-lysine, M-methionine, F-

36

phenylalanine, P-proline, S-serine, T-threonine, W-tryptophan, Y-tyrosine and V-valine.

Brief Description of Drawings

5

10

15

20

25

Figure 1 is a diagram showing the functioning of 6-deoxyerythronolide B synthase (DEBS), a modular PKS producing 6-deoxyerythronolide B, a precursor of erythromycin A.

Figure 2 gives the amino acid sequence comparison of the AT domains of representative Type I PKS gene clusters. The motifs GQG, GHS and LPTY are marked at the base of the figure along with the arginine and the motif defined in the invention as defining specificity. The abbreviations used at the side to define the PKS used are: ave: avermectin, debs: erythromycin, epo: epothilone, sor: soraphen, fkb: FK506, rap: rapamycin, tyl: tylosin, mon: monensin, nid: niddamycin, nys: nystatin, rif: rifamycin. The numbers represent the module number. The letter a at the end of the designation indicates malonyl-CoA specific AT, the letter p indicates methylmalonyl-CoA specific AT, and the letter b indicates ethylmalonyl-CoA specific AT. Further types of AT with unusual or ill-defined AT specificity are indicated with letter x. Due to the numbers of sequences considered, in the pileup each section of 50 amino acids

37

spreads over two pages. The sequences of the monensin ATs are unpublished. They are set out in PCT/GB00/02072.

Figure 3 shows a three-dimensional representation of the active site of the *E. coli* acyltransferase. The spatial arrangement of the motifs described in the text are shown by arrows and the atoms shown in bold.

Figure 4 shows the enzymatic steps that convert 6-deoxyerythronolide B into erythromycin A in Saccharopolyspora erythraea.

Figure 5 shows the DNA sequence from the monensin PKS encoding the loading AT used in Example 8.

Modes for Carrying Out the Invention

15 <u>Example 1</u>

10

20

25

Construction of plasmid pHP41

Plasmid pHP41 is a pCJR24-based plasmid containing the DEBS1 PKS gene comprising a loading module, the first and second extension modules of DEBS and the chain terminating thioesterase. The motif YASH of the AT domain of first module has been altered to HAFH. Plasmid pHP41 was constructed by several intermediate plasmids as follows. Plasmid pD1AT2 (Oliynyk, M. et al. Chem. Biol. (1996) 3:833-839) was digested with NdeI and XbaI. A

~11kbp fragment was isolated by gel electrophoresis and

38

the DNA purified from the gel. This fragment was ligated into pCJR24 (Rowe, C.J. et al. Gene (1998) 216:215-223) that had been linearised by digestion with NdeI and XbaI and treated with alkaline phosphatase. The ligation mixture was used to transform electrocompetent E. coli DH10B cells and individual clones checked for the desired plasmid pCJR26. Plasmid pCJR26 was identified by restriction pattern. pCJR26 was transformed into E. coli strain ET12567 (McNeil, D.J. et al. Gene (1992) 111:61-68) and an individual colony grown overnight to isolate demethylated DNA. This DNA was linearised using MscI and AvrII and the ~13kb fragment (Fragment A) isolated by gel electrophoresis and purification from the gel.

10

15

A DNA segment of the eryAI gene (start nucleotide 45368, end nucleotide 34734) from S.erythraea extending from nucleotide 42104 to nucleotide 41542 was amplified by PCR using the following oligonucleotide primers; 5'TTTTTTTGGCCAGGGTTGGCAGTGGGGGGGCA-3' and 5'TTTTTTACGGCCAGCCGCTTGGCGCGCGGAT-3'. The DNA from a plasmid designated pCJR65 derived from pCJR24 and DEBS1TE was used as a template. The design of the primers introduced a MscI site at nucleotide 42105 and the second primed across a BstXI site at position 41546. The 574bp PCR

39

product was treated with T4 polynucleotide kinase and ligated to plasmid pUC18 that had been linearised by digestion with SmaI and then treated with alkaline phosphatase. The ligation mixture was used to transform electrocompetent E. coli DH10B and individual clones checked for the presence of the desired plasmid pHP39. Plasmid pHP39 was identified by restriction pattern and sequence analysis. Demethylated DNA was produced by transforming E. coli strain ET12567 with plasmid DNA. The resulting DNA was linearised by digestion with MscI 10 and BstXI and the resulting 552bp fragment (Fragment B) isolated by gel electrophoresis and purified from the gel. A DNA segment of the eryAI gene from S.erythraea extending from nucleotide 41557 to nucleotide 41120 was amplified by PCR using the following oligonucleotide 15 primers; 5'-CGGTGCCTAGGTGCACCGACTCCCAGTCC-3 5'-TTTTTCCAAGCGGCTGGCCGTGGACCACGCGTTCCACTCCTCGCACGTCGAGACGAT -3'. DNA from plasmid pCJR65 was used as a template. The design of the primers introduced an AvrII site at nucleotide 41125 and the second primed across a BstXI 20 site at nucleotide 41557 and mutated the amino acid sequence YASH to HAFH (encoded by nucleotides 41537-41526). The 442bp PCR product was treated with T4 polynucleotide kinase and ligated to plasmid pUC18 that

40

had been linearised by digestion with SmaI and then treated with alkaline phosphatase. The ligation mixture was used to transform electrocompetent E. coli DH10B and individual clones checked for the presence of the desired plasmid pHP40. Plasmid pHP40 was identified by restriction pattern and sequence analysis. Plasmid pHP40 was linearised by digestion with restriction enzymes AvrII and BstXI, and a 427bp fragment (Fragment C) isolated by gel electrophoresis and purified from the 10 gel. Fragments A, B, and C were ligated together and the resulting ligation mixture used to transform electrocompetent E. coli DH10B. Individual clones were checked for the presence of an insert derived from DEBS1. The resulting plasmid was designated pHP41. Sequence 15 analysis was used to confirm the clone contained the correct motif HAFH.

Example 2

Construction of S. erythraea NRRL2338 JC2/pHP41 and production of triketides

S. erythraea NRRL2338 JC2 contains a deletion of the eryAI, eryAII and eryAIII apart from the TE (Rowe, C.J. et al. Gene 216, 215-223). Plasmid pHP41 was used to transform S. erythraea NRRL2338 JC2 protoplasts using the

41

TE as a homology region. Thiostrepton resistant colonies were selected on R2T20 agar containing 40 $\mu g/ml$ thiostrepton. S. erythraea NRRL2338 JC2 (pHP41) was plated onto SM3 agar (see patent application WO 00/01827) containing 40 µg/ml thiostrepton and allowed to grow for 11 days at 30°C. Approximately 1cm² of the agar was homogenised and extracted with a mixture of 1.2ml ethyl acetate and 20 µl formic acid. The solvent was decanted and removed by evaporation and the residue dissolved in methanol and analysed by GC/MS. The major products were 10 identified by comparison with authentic standards (Oliynyk, M. et al. Chem. Biol. (1996) 3:833-839) as triketide lactones (2S,3R,5R)-2-methyl-3,5-dihydroxy-nhexanoic δ -lactone (AAP, i.e. Acetate, Acetate, 15 Propionate incorporation), (2S, 3R, 5R)-2-methyl-3,5dihydroxy-n-heptanoic δ -lactone (PAP), (2R, 3S, 4S, 5R) 2, 4-dimethyl-3,5-dihydroxy-n-heptanoic δ -lactone (PPP) and (2R,3S,4S,5R) 2, 4-dimethyl-3,5-dihydroxy-n-hexanoic δ lactone (APP). These products were identified as their 20 ammonium adducts corresponding to exact mass 144, 158, 172 and 158. Four products were produced because in this strain, and under the conditions of the experiment the loading module loads both acetate and propionate and the modified AT loads malonyl-CoA and methylmalonyl-CoA.

42

Only three triketide lactone peaks could be observed in the GC/MS spectra under standard conditions, this was due to the co-elution of the equivalent mass APP and PAP compounds. An isocratic gradient was used to verify this peak was comprised of two components. In further sets of experiments S. erythraea JC2 (pHP41) was used to inoculate 5ml TSB containing 5 µg/ml thiostrepton. After three days growth 1.5ml of this culture was used to inoculate 25ml SM3 media containing 5 µg/ml thiostrepton in a 250ml flask. The flask was incubated at 30 °C, 10 250rpm for 6 days. At this time the supernatant was adjusted to pH3.0 with formic acid and extracted twice with an equal volume of ethyl acetate. The solvent was removed by evaporation and the residue analysed by GC/MS. 15 In each experiment we could identify the 4 products AAP, PAP, PPP and APP but the absolute ratios and quantities were variable, presumably depending on exact media and growth conditions within each flask (figure 6).

20 Example 3

Construction of S. erythraea NRRL2338 (pHP41) and its use to produce 12-desmethyl erythromycin B.

Plasmid pHP41 was used to transform S. erythraea
NRRL2338 protoplasts. Thiostrepton resistant colonies

43

were selected on R2T20 agar containing 40 μg/ml thiostrepton. Several clones were tested for the presence of pHP41 integrated into the chromosome by Southern blot hybridisation of their genomic DNA with DIG labelled vector DNA. A clone with a correctly integrated copy of pHP41 was identified in this way. S. erythraea NRRL2338 (pHP41) was used to inoculate 5ml TSB containing 5 μg/ml thiostrepton. After three days growth 1.5ml of this culture was used to inoculate 25ml EryP media (see patent application WO 00/00500) containing 5 µg/ml thiostrepton in a 250ml flask. The flask was incubated at 30 °C, 250rpm for 6 days. At this time the supernatant was adjusted to pH9.0 with ammonia and extracted twice with an equal volume of ethyl acetate. The solvent was removed by evaporation and the residue analysed by HPLC/MS. A peak of molecular mass m/z (M+H)=704 was observed required for C-12 desmethyl erythromycin B in addition to a peak corresponding to erythromycin A (M+H)=734. Other peaks corresponding to partially processed erythromycin intermediates could be identified.

Example 4

5

15

20

Construction of plasmid pHP048

Plasmid pHP048 is a pCJR24-based plasmid containing the
DEBS1 PKS gene comprising a loading module, the first and

44

second extension modules of DEBS1 and the chain terminating thioesterase. The motif YASH of the AT domain of first module has been altered to HASH. Plasmid pHP048 was constructed by several intermediate plasmids as follows.

5

15

20

A DNA segment of the eryAI gene from S.erythraea extending from nucleotide 41557 to nucleotide 41120 was amplified by PCR using the following oligonucleotide primers; 5'-CGGTGCCTAGGTGCACCGACTCCCAGTCC-3' and 5'-TTTTTCCAAGCGGCTGGCCGTGGACCACGCGTCGCACTCCTCGCACGTCGAGACGAT -3'. The DNA from plasmid pCJR65 was used a as template. The design of the primers introduced a AvrII site at nucleotide 41125 and the second extended to a BstXI site at nucleotide 41557, also mutated the amino acid sequence YASH (encoded by nucleotides 41537-41526) to HASH. 442bp PCR product was treated with T4 polynucleotide kinase and ligated to plasmid pUC18 that had been linearised by digestion with SmaI and then treated with alkaline phosphatase. The ligation mixture was used to transform electrocompetent E. coli DH10B and individual clones checked for the presence of the desired plasmid Plasmid pHP022 was identified by restriction pattern and sequence analysis. Plasmid pHP022 was linearised by digestion with restriction enzymes AvrII

45

and BstXI, and the fragment (Fragment D) isolated by gel electrophoresis and purified from the gel. Fragment D was ligated with Fragments A and B described previously and the resulting ligation mixture used to transform electrocompetent E. coli DH10B. Individual clones were checked for the presence of an insert derived from DEBS1. The resulting plasmid was designated pHP048. Sequence analysis was used to confirm the clone contained the correct motif HASH.

10

Example 5

Construction of S. erythraea NRRL2338 JC2 (pHP048) and its use to produce triketides

- S. erythraea NRRL2338 JC2 contains a deletion of the

 15 eryAI, eryAII and eryAIII apart from the TE (Rowe, C.J.

 et al. Gene 216, 215-223). Plasmid pHP048 was used to

 transform S. erythraea NRRL2338 JC2 protoplasts using the

 TE as a homology region. Thiostrepton resistant colonies

 were selected on R2T20 agar containing 40µg/ml
- 20 thiostrepton. S. erythraea JC2 (pHP048) was used to inoculate 5ml TSB containing 5 μg/ml thiostrepton. After three days growth 1.5ml of this culture was used to inoculate 25ml SM3 media containing 5 μg/ml thiostrepton in a 250ml flask. The flask was incubated at 30 °C,

46

250rpm for 6 days. At this time the supernatant was adjusted to pH3.0 with formic acid and extracted twice with an equal volume of ethyl acetate. The solvent was removed by evaporation and the residue analysed by GC/MS. A mixture of products were identified as their ammonium adducts corresponding to the AAP, PAP, APP and PPP triketide lactones as described in example 2. In this example, under the media/growth conditions described the PKS with the HASH change is more catalytically active than the HAFH change (example 2) as judged by total amounts of triketide lactone produced, however in this case the modified PKS appears to display lower selectivity towards acetate as judged by the ratio of AAP

15

20

25

10

Example 6

to PPP triketide lactone.

Construction of plasmid pHP47

Plasmid pHP47 is a pCJR24-based plasmid containing the DEBS1 PKS gene comprising a loading module, the first and second extension modules of DEBS1 and the chain terminating thioesterase. The motif YASH of the AT domain of first module has been altered to VAGH. Plasmid pHP47 was constructed by several intermediate plasmids as follows.

47

A DNA segment of the eryAI gene from S.erythraea extending from nucleotide 41557 to nucleotide 41120 was amplified by PCR using the following oligonucleotide primers; 5'-CGGTGCCTAGGTGCACCGACTCCCAGTCC-3' and 5'-TTTTTCCAAGCGGCTGGCCGTGGACGTCGCGGGGCACTCCTCGCACGTCGAGACGAT The DNA from plasmid pCJR65 was used as a template. The design of the primers introduced a AvrII site at nucleotide 41125 and the second extended to a BstXI site at nucleotide 41557, also mutated the amino acid sequence YASH (encoded by nucleotides 41537-41526) to VAGH. The 10 442bp PCR product was treated with T4 polynucleotide kinase and ligated to plasmid pUC18 that had been linearised by digestion with SmaI and then treated with alkaline phosphatase. The ligation mixture was used to transform electrocompetent E. coli DH10B and individual 15 clones checked for the presence of the desired plasmid pHP46. Plasmid pHP46 was identified by restriction pattern and sequence analysis. Plasmid pHP46 was linearised by digestion with restriction enzymes AvrII and BstXI, and the fragment (Fragment E) isolated by gel 20 electrophoresis and purified from the gel. Fragment E was ligated with Fragments A and B described previously and the resulting ligation mixture used to transform electrocompetent E. coli DH10B. Individual clones were

48

checked for the presence of an insert derived from DEBS1.

The resulting plasmid was designated pHP47. Sequence analysis was used to confirm the clone contained the correct motif VAGH.

5

20

Example 7

Construction of plasmid pLS007

Plasmid pLS007 contains the crotonyl-CoA reductase

(CCR) gene from S. cinnamonensis that is believed to

influence the level of ethylmalonyl-CoA within the cell.

Plasmid pSG142 (Gaisser et al. Mol. Microbiol. (2000) 36

391-401) places genes under the control of the actI

promoter and can be used to integrate either in the right hand side of the erythromycin gene cluster or in the act

promoter region of a previously transformed actinomycete.

Two oligonucleotide primers; 5'-

GGCAAACATATGAAGGAAATCCTGGACGCG-3' and 5'-

TCCGCGGATCCTCAGTGCGTTCAGATCAGTGC-3' were used to amplify the *S. cinnamonensis* CCR gene using genomic DNA as template. The design of the primers incorporated *NdeI* and *BamHI* restriction sites to facilitate cloning. The 1.4kb PCR product was isolated by gel electrophoresis and purified from the gel and ligated with pSG142 that had been digested with NdeI and BglII. The resulting

49

ligation mixture was used to transform electrocompetent E. coli DH10B cells. Plasmid pLS003 was identified by restriction analysis and sequencing to ensure errors were not introduced during amplification. A discrepancy with the published sequence was identified. However, further analysis by comparison with other published CCR protein sequences indicated pLS003 was correct. Plasmid pLS003 was digested with NdeI and XbaI and the resulting 4.5kb fragment (fragment F) isolated by gel electrophoresis and purified from the gel. This fragment was ligated to pLSB2 a derivative of pKC1132 containing the actI/actII promoter region behind an NdeI site. Plasmid pLSB2 was digested with NdeI and XbaI and the resulting ~4kb fragment (Fragment G) purified by gel electrophoresis and purified from the gel. Fragments F and G were ligated together and the resulting ligation mixture was used to transform electrocompetent E. coli DH10B cells. Plasmid pLS007 was identified by restriction analysis.

20 Example 8

5

10

15

Construction of S. erythraea NRRL2338 JC2 (pHP47/pLS007) and its use to produce triketides

S. erythraea NRRL2338 JC2 contains a deletion of the eryAI, eryAII and eryAIII apart from the TE (Rowe, C.J.

50

et al. Gene 216, 215-223). Plasmid pHP47 was used to transform S. erythraea NRRL2338 JC2 protoplasts using the TE as a homology region. Thiostrepton resistant colonies were selected on R2T20 agar containing 40 μg/ml thiostrepton. PLS007 was used to transform protoplasts of S. erythraea NRRL2338 JC2 (pHP47), thiostrepton and apramycin resistant clones were selected on R2T20 agar containing 40 µg/ml thiostrepton and 50 µg/ml apramycin plus 10mM magnesium chloride and the resistance markers verified by plating on tapwater media containing the same 10 antibiotics. S. erythraea NRRL2338 JC2 (pHP47/pLS007) was used to inoculate 5ml TSB containing 5 µg/ml thiostrepton and 50 µg/ml apramycin. After three days growth 1.5ml of this culture was used to inoculate 25ml SM3 media containing 5 µg/ml thiostrepton and 50 µg/ml apramycin in 15 a 250ml flask. The flask was incubated at 30°C, 250rpm for 6 days. At this time the supernatant was adjusted to pH3.0 with formic acid and extracted twice with an equal volume of ethyl acetate. The solvent was removed by evaporation and the residue analysed by GC/MS. In this 20 experiment amounts of triketide product were lower but a mixture of products could be identified as their ammonium adducts corresponding to exact masses 158 172 and 186.

51

Example 9

Construction of S. erythraea NRRL2338 (pHP47) and its use to produce erythromycins.

Plasmid pHP47 was used to transform S. erythraea NRRL2338 protoplasts. Thiostrepton resistant colonies were selected on R2T20 agar containing 40 µg/ml thiostrepton. S. erythraea NRRL2338 (pHP47) was used to inoculate 5ml TSB containing 5 µg/ml thiostrepton. After three days growth 1.5ml of this culture was used to 10 inoculate 25ml EryP media containing 5 µg/ml thiostrepton in a 250ml flask. The flask was incubated at 30°C, 250rpm for 6 days. At this time the supernatant was adjusted to pH9.0 with ammonia and extracted twice with an equal volume of ethyl acetate. The solvent was removed by 15 evaporation and the residue analysed by HPLC/MS. Peaks of mass m/z (M+H)=734 corresponding to erythromycin A were observed.

Example 10

20 <u>Construction of plasmid pSGK051</u>

Plasmid pSGK051 is a pPFL43 based plasmid (WO 00/00500). The motif HAFH of the AT domain of the loading domain has been altered to YASH. Plasmid pSGK051 was constructed by several intermediate plasmids as

52 -

follows.

10

Plasmid pPFL43 was linearised by digestion with restriction enzymes NcoI and NotI and a 858bp fragment (Fragment Q) isolated by gel electrophoresis and purified from the gel.

A DNA segment of the monensin loading domain from nucleotide 16360-17366 (see figure 5 and PCT/GB00/02072) was amplified by PCR using the following oligonucleotide primers; 5'-

GGGGACGCGCCAAGGCCCACCACCTGAAGGTCAGCTACGCCTCCCACTCCCCGC ACATGGACCCCAT-3' and 5'-GGCTAGCGGGTCCTCGTCCGTGCCGAGGTCA-3'. The design of the primers amplified across a NotI site at nucleotide 16367 and changed the amino acid sequence HAFH to YASH at nucleotides 16398-16409, the second introduced a NheI site equivalent to that in 15 pPFL43. The DNA from plasmid pPFL43 was used as a template. The 1006bp PCR product was treated with T4 polynucleotide kinase and ligated to plasmid pUC18 that had been linearised by digestion with SmaI and treated 20 with alkaline phosphatase. The ligation mixture was used to transform electrocompetent E. coli DH10B and individual clones checked for the presence of the desired plasmid pCSAT9. Plasmid pCSAT9 was identified by

restriction pattern and sequence analysis. Plasmid

53

pCSAT9 was linearised by digestion with restriction enzymes NotI and NheI and a 995bp fragment (Fragment R) isolated by gel electrophoresis and purified from the gel. Plasmid pPFL43 was digested with NcoI and NheI to remove a 1.8kb fragment and the larger fragment (Fragment S) isolated by gel electrophoresis and purified from the gel. Fragments Q, R and S were ligated together and the resulting ligation mixture used to transform electrocompetent E. coli DH10B. Individual clones were checked for the desired plasmid pSGK051. The resulting plasmid was analysed by restriction digest and sequenced to confirm the presence of the correct motif YASH.

Example 11

15

20

Construction of S. erythraea NRRL2338 JC2/pSGK051 and production of triketides

Plasmid pSGK051 was used to transform *S. erythraea*NRRL2338 JC2 protoplasts using the TE as a homology region. Thiostrepton resistant colonies were selected on R2T20 agar containing 40 µg/ml thiostrepton. *S. erythraea* NRRL2338 JC2 (pSGK051) was plated onto R2T20 agar containing 40 µg/ml thiostrepton and allowed to grow for 11 days at 30°C. Approximately 1cm² of the agar was homogenised and extracted with a mixture of 1.2ml ethyl

54

acetate and 20 μ l formic acid. The solvent was decanted and removed by evaporation and the residue dissolved in methanol and analysed by GC/MS. The major products were identified by comparison with authentic standards as triketide lactones (2S,3R,4S,5R)-2,4-dimethyl-3,5-dihydroxy-n-heptanoic δ -lactone and (2S,3R,4S,5R)-2,4-dimethyl-3,5-dihydroxy-n-hexanoic δ -lactone.

Example 12

10

15

20

Construction of S. erythraea NRRL2338 (pSGK051) and its use to produce erythromycins.

Plasmid pSGK051 was used to transform *S. erythraea*NRRL2338 protoplasts. Thiostrepton resistant colonies

were selected on R2T20 agar containing 40 µg/ml

thiostrepton. *S. erythraea* NRRL2338 (pSGK051) was plated

onto R2T20 agar containing 40 µg/ml thiostrepton and

allowed to grow for 10 days at 30°C. Approximately 2cm²

of the agar was homogenised and extracted with a mixture

of 1.2ml ethyl acetate and 20 µl dilute ammonia. The

solvent decanted and was removed by evaporation and the

residue analysed by HPLC/MS. Peaks of mass m/z (M+H)=734

and 720 could be observed alongside likely products of

incomplete processing. Comparison to authentic standards

proved the compounds produced were erythromycin A and 13-

55

methyl erythromycin A.

56

PCT/GB01/03642

CLAIMS:

WO 02/14482

- A method of synthesising a compound whereof at least a portion is the product of a polyketide synthase 5 (PKS) enzyme complex or is derived from such a product, said PKS enzyme complex including at least one acyltransferase (AT) domain; said method comprising the steps of (i) providing said PKS enzyme complex in which said AT domain has been altered to change selectively a 10 minor proportion of amino acid residues, the altered residue(s) comprising one or more residues of one or more motifs which are present in the active site pocket of the AT domain and which influence the substrate specificity of the AT domain, the alteration affecting the substrate 15 specificity; and (ii) effecting synthesis by means of said PKS enzyme complex to produce a compound or mixture of compounds different from what could have been produced by means of a PKS enzyme in which said AT domain had not been altered.
- 20 2. A method according to claim 1 wherein said motif comprises a four-residue sequence corresponding to the YASH motif of the AT domain of the first module of DEBS.
- 3. A method of synthesising a compound whereof at25 least a portion is the product of a polyketide synthase

57

(PKS) enzyme complex or is derived from such a product, said PKS enzyme complex including at least one acyltransferase (AT) domain; said method comprising the steps of (i) providing said PKS enzyme complex in which said AT domain has been altered to change selectively a minor proportion of amino acid residues, the altered residue(s) comprising one or more residues of a motif which influences the substrate specificity of the AT domain and which comprises a four-residue sequence corresponding to the YASH motif of the AT domain of the first module of DEBS, the alteration affecting the substrate specificity; and (ii) effecting synthesis by means of said PKS enzyme complex to produce a compound or mixture of compounds different from what could have been produced by means of a PKS enzyme in which said AT domain had not been altered.

5

10

15

- 4. A method according to claims 1, 2 or 3 wherein said motif was located by a) determining the sequence of the AT domain and b) performing sequence alignment with a plurality of sequences of other AT domains.
- 5. A method according to any preceding claim wherein the PKS enzyme complex is at least part of a modular type I PKS enzyme complex.

58

- 6. A method according to any preceding claim wherein said alteration of the AT domain affects less than 5% of the residues.
- A method according to any preceding claim
 wherein said alteration alters a motif selected from
 XAFH, XASH, and XAGH and/or creates such a motif.
 - 8. A method according to claim 7 wherein the motif is XAGH and X is selected from F, T, V and H.
- 9. A method according to claim 7 wherein the motif 10 is XAFH and X is H.
 - 10. A method according to claim 7 wherein the motif is XASH and X is selected from Y, H, W and V.
 - 11. A method according to any of claims 1-10 wherein said alteration produces or alters a motif containing proline.

15

20

- 12. A method according to any preceding claim wherein in addition to the alteration to one or more residues of said motif(s), one or more additional residues in or adjacent the substrate binding pocket have been altered.
- 13. A method according to claim 12 wherein said additional altered residue(s) comprise one or more of a) the residue immediately downstream of the motif, b) the residue three residues downstream from the GQG motif, c) the residue immediately downstream of the GHS motif, and

59

d) the residue four residues downstream of the conserved arginine residue.

14. A method according to any preceding claim wherein the alteration produces a motif specific for malonyl-CoA and the motif is followed by S which was produced by alteration if not already present.

5

10

15

- 15. A method according to any of claims 1-13 wherein the alteration produces a motif specific for methylmalonyl-CoA and the motif is followed by S, G, C or T which was produced by alteration if not already present.
- 16. A method according to any of claims 1-13 wherein the alteration produces a motif specific for methylmalonyl-CoA, and the residue following the GHS motif in the active site is Q which was produced by alteration if not already present.
- 17. A method according to any of claims 1-13 wherein the alteration produces a motif specific for malonyl-CoA, and the residue following the GHS motif in the active site is V, I or L which was produced by alteration if not already present.
- 18. A method according to any of claims 1-13 wherein the alteration produces a motif specific for methylmalonyl-CoA, and the residue 3 residues downstream

WO 02/14482 PCT

5

60

PCT/GB01/03642

of the GQG motif is W which was produced by alteration if not already present.

- 19. A method according to any of claims 1-13 wherein the alteration produces a motif specific for malonyl-CoA, and the residue 3 residues downstream of the GQG motif is R, H or T which was produced by alteration if not already present.
- 20. A method according to any of claims 1-13
 wherein the alteration produces a motif specific for

 10 malonyl-CoA and the residue 4 residues downstream of the conserved R as found as residue 252 in the first module of DEBS is M which was produced by alteration if not already present.
- 21. A method according to any of claims 1-13

 15 wherein the alteration produces a motif specific for methylmalonyl-CoA and the residue 4 residues downstream of the conserved R as found as residue 252 in the first module of DEBS is I or L which was produced by alteration if not already present.
- 22. A method according to any of claims 1-13
 wherein the alteration produces a motif specific for
 ethylmalonyl-CoA and the residue 4 residues downstream of
 the conserved R as found as residue 252 in the first
 module of DEBS is W which was produced by alteration if
 25 not already present.

61

- 23. A method according to any preceding claim wherein the AT domain has an active site with a GHS motif, and said motif which is altered starts 80-110 residues downstream of said GHS motif.
- 24. A method according to any preceding claim wherein said step (i) of providing said PKS enzyme complex comprises providing a nucleic acid sequence encoding said complex and effecting expression thereof.
- 25. A method according to claim 24 wherein
 10 expression is effected is an organism capable of producing polyketides.

15

- 26. A method according to claim 24 or claim 25 wherein said nucleic acid sequence has been subjected to site directed mutagenesis so that it encodes said altered AT domain.
- 27. A method according to claim 24, 25 or 26 wherein the AT domain prior to alteration is naturally expressed in a first organism and the altered AT is expressed in a second organism which is better able than the first organism to supply a substrate for which the alteration has increased specificity and/or which is less well able than the first organism to supply a substrate for which the alteration has reduced specificity.
- 28. A method according to any preceding claim
 25 wherein said PKS includes said AT domain and a second

62

domain which is naturally coupled thereto prior to the alteration thereof to receive a substrate transferred to it by the AT; and the alteration causes the AT to act to transfer a different substrate to the second domain.

- 5 29. A method according to any preceding claim wherein said PKS includes said AT domain and its natural cognate ACP domain which, prior to the alteration, is adapted to receive a substrate transferred to it by the AT; and the alteration causes the AT to act to transfer a different substrate to said cognate ACP domain.
 - 30. A method according to any preceding claim wherein said PKS including the altered AT domain is spliced to a hybrid PKS.
- 31. A polyketide compound or derivative thereof or compound whereof a portion is a polyketide or derivative thereof, which compound is obtainable by a method according to any preceding claim wherein the compound differs from a compound resulting from synthesis effected by means of said PKS enzyme complex without the alteration of said AT domain.
 - 32. Nucleic acid encoding a PKS enzyme complex including an altered AT domain as defined in any of claims 1-30.
- 33. A vector including a nucleic acid according to claim 32.

63

- 34. A host organism containing nucleic acid according to claim 32 and able to express the PKS enzyme complex.
- 35. A host organism according to claim 34 which is adapted to synthesise a compound whereof at least a portion is a polyketide resulting from the action of the PKS enzyme complex.

5

10

15

20


- 36. A method of synthesising a polyketide synthase (PKS) enzyme complex, said PKS enzyme complex including at least one acyltransferase (AT) domain; said method comprising altering said AT domain to change selectively a minor proportion of amino acid residues, the altered residue(s) comprising one or more residues of one or more motifs which are present in the active site pocket of the AT domain and which influence the substrate specificity of the AT domain, the alteration affecting the substrate specificity.
 - 37. A method according to claim 36 wherein said motif comprises a four-residue sequence corresponding to the YASH motif of the AT domain of the first module of DEBS.
 - 38. A method of synthesising a polyketide synthase (PKS) enzyme complex, said PKS enzyme complex including at least one acyltransferase (AT) domain; said method comprising altering said AT domain to change selectively

64

a minor proportion of amino acid residues, the altered residue(s) comprising one or more residues of a motif which influences the substrate specificity of the AT domain and which comprises a four-residue sequence corresponding to the YASH motif of the AT domain of the first module of DEBS, the alteration affecting the substrate specificity.

5

39. A PKS enzyme complex as produced by the method of claims 36, 37 or 38.



	1	•	2/26		50
atave00x	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atdebs00p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atepo06p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atepo07p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atepo01p	~~~~~~~	~~~~~~~	~~~~~~~~	~~~~~~	~~~~~~~
atepo05p	~~~~~~~	~~~~~~~	~~~~~~~~	~~~~~~~	~~~~~~~
atsora1x	~~~~~~~	~~~~~~~	~~~~~~~~	~~~~~~~~	~~~~~~~
atfkb01p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atfkb09p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atrap03p	~~~~~~~	~~~~~~~	~~~~~~~~	~~~~~~~	~~~~~~~
atrap06p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atrap04p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~PLVI
atrap13p	~~~~~~~	~~~~~~~	~~~~~~A	EEAQPVETPV	VASDVLPLVI
atrap01p	~~~~~~~	~~~~~~~	~~~~~~~~	~~~~~~~	~~~~~~~
atrap07p	~~~~~~~	~~~~~~~	~~~~~~~~	~~~~~PV	VASELVPLVI
atrap10p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atfkb04x	~~~~~~~		~~~~~~~	~~~~~~	~~~~~~
attyl04p	~~~~~~~	~~~~~~VV	REAAGRLAEV	VEAGGVGLAD	VAVTMAGRSR
attyl06p	~~~~~~~	~~~~~~~	~~~~GRLAEV		VAVTMAGRSR
attyl01p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~MAGRSR
attyl02p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
attyl00p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~D	VAVTMADRSR
atnid05b	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atty105b	~~~~~~~	~~~~~~~		~~~~~AAL	REOSTRLLND
atnid06x	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atdebs01p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atmon02p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atmon10p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~
atmon04p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atmon07p	~~~~~~~	~~~~~~~	~~~~~~~~	~~~~~~~	~~~~~~~
atmon11p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atmon12p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atmon05b	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~~
atmon01p	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atdebs02p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	
atdebs06p	~~~~~~~	~~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atave01p	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~
atave07p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~
atave06p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atave09p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~
atnys01p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atnys11p	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~~
atrif05p	~~~~~~	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~
atrif07p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~
atrif08p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atrif10p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~
atrif03p	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atrif06p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atrif04p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atrif01p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atnys02p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atfkb02p	~~~~~~~~	~~~~~~~		~~~~~~	~~~~~~~
atave11p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atdebs03p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~
atnid04p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	
atdebs05p	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~
atdebs04p	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~	~~~~~~
- <u>-</u> -					

3/26

atave02a LFAFQVALHR LLTDGYHITP HYYAGHSLGE ITAAHLAGIL TLTDATTLIT atave05a LFAFQVALHR LLTDGYHITP HYYAGHSLGE ITAAHLAGIL TLTDATTLIT atave04a LFAFQVALHR LLTDGYHITP HYYAGHSLGE ITAAHLAGIL TLTDATTLIT atave08a LFAFQVALHR LLTDGYHITP HYYAGHSLGE ITAAHLAGIL TLTDATTLIT atave03a LFAFQVALHR LLTDGYHITP HYYAGHSLGE ITAAHLAGIL TLTDATTLIT atrap02a LFALQVALFG LL.ESWGVRP DAVVGHSVGE LAAGYVSGLW SLEDACTLVS atrap11a LFALQVALFG LL.ESWGVRP DAVVGHSVGE LAAGYVSGLW SLEDACTLVS atrap08a LFALQVALFG LL.ESWGVRP DAVVGHSVGE LAAGYVSGLW SLEDACTLVS atrap12a LFAMOVALFG LL.ESWGVRP DAVIGHSVGE LAAAYVSGVW SLEDACTLVS atrap05a LFALQVALFG LL.ESWGVRP DAVVGHSVGE LAAGYVSGLW SLEDACTLVS atrap09a LFALQVALFG LL.ESWGVRP DAVIGHSVGE LAAAYVSGLW SLEDACTLVS atfkb03a VFALQVALSA QL.DAWGVRP DVLVGHSIGE LAAAYVAGVW SLDDATELVS atfkb07x HFAHQIALTA LL.RSWGITP HAVIGHSLGE ISAACAAGVL SIGDASALLA atfkb08x LFAHQAAFTA LL.RSWDITP HAVIGHSLGE ITAAYAAGIL SLDDACTLIT atnid01a LFALQTALYR TL.TARGTQA HLVLGHSVGE ITAAHIAGVL DLPDAARLIT atnid03a LFALQTALYR TL.TARGTQA HLVLGHSVGE ITAAHIAGVL DLPDAARLIT atnid02a LFALQTALYR TL.TAHGTQA HLVLGHSVGE ITAAHIAGVL DLPDAARLIT atnid00a LFALQTALYR TL.TARGTQA HLVLGHSVGE ITAAHIAGVL DLPDAARLIT atfkb10a LFTLEVALLR LL.EHWGVRP DVVVGHSVGE VTAAYAAGVL TLADATTLIV atrap14a IFAMEAALFG LL.EDWGVRP DFVAGHSIGE ATAAYASGML SLENVTTLIV atmon06a LFALOVGLAR LW.ESVGVRP DVVLGHSIGE IAAAHVAGVF DLADACRVVG atmon08a LFALQVGLAR LW.ESVGVRP DVVLGHSIGE IAAAHVAGVF DLADACRVVG atmon09a LFALQVGLAR LW.ESVGVRP DVVLGHSIGE IAAAHVAGVF DLADACRVVG atepo02a LFAVEYALTA LW.RSWGVEP ELLYGHSIGE LVAACVAGVF SLEDGVRLVA atepo03x LFTVEYALTA LW.RSWGVEP ELVAGHSAGE LVAACVAGVF SLEDGVRLVA atepo08a LFALEYALAA LF.RSWGVEP ELVAGHSLGE LVAACVAGVF SLEDAVRLVV atepo00a LFTFEYALAA LW.RSWGVEP ELVAGHSIGE LVAACVAGVF SLEDAVFLVA atepo04a LFALEYALAA LW.RSWGVEP HVLLGHSIGE LVAACVAGVF SLEDAVRLVA atnid07a LFAVETALFR LF.ESWGLMP DVLLGHSIGG LAAAYAAGVF SSADAVRLVA attyl07a LFAVEVALHR LL.EHWGMRP DLLLGHSVGE LAAAHVAGVL DLDDACALVA atsor02a LFALEVALFQ LL.QSFGLKP ALLLGHSIGE LVAAHVAGVL SLQDACTLVA atsorbla LFALEVALFE LL.QSFGLKP ALLLGHSIGE LVAAHVAGVL SLQDACTLVA atnys09a LFAVEVALYR LI.ESFGVRP DHLAGHSVGE IVAAHLAGVL SLADAATLVA atnys12a LFAVEVALFR LL.TSWGLTP DYLAGHSVGE LAAAHVAGVL SLDDACTLVA atnys16a LFAVEVALFR LV.ASWGVGP EFVAGHSVGE IAAAHVAGVF SLVDACRLVV atnys17a LFAVEVALFR LV.ASWGVGP EFVAGHSVGE IAAAYVAGVF SLVDACRLVV atnys03a LFAVEVALYR LV.ASLGVTP DFVGGHSIGE LAAAHVAGVL SLEDACTLVA atnys07a LFAIEVALFR LV.ESWGVAP DFVAGHSIGE IAAAHVAGVF SLEDACTLVA atnys08a LFAVEVALFR LV.ERWGVRP DFVAGHSIGE IAAAHVAGVF SLEDACRLVA atnys05a LFAVEVALFR LV.ESWGVRP DFVAGHSIGE IAAAHVVGVF SLEDACRLVA atnys06a LFAIEVALFR LV.ESWGVRP DFVAGHSIGE IAAAHVVGVF SLEDACRLVA atnys04a LFAIEVALFR LL.EAWGITP DFVAGHSIGE IAAAHVAGVL SLGDACRLVV atnys14a LFAVEVALYR LI.ESWGVRP DFVAGHSVGE LAAAHVAGVL SLDDACRLVA atnys00a LFAVEVALHR LV.ASLGVTP DFVGGHSVGE IAAAHVAGVL SLEDACRLVA atnys10a LFAVEVALFR LV.ESWGVRP DFVAGHSIGE IAAAHVAGVL TLEDACRLVA atnys18a LFAVEVALYR LL.ASWGIRP DHVTGHSIGE ITAAHVAGVL TLADACTLVA atnys13a LFAVEVALFR LA.ESWRLTP DFVAGHSIGE IAAAHVAGVL SLEDACTLVA atave10a LFAFEVALFR LL.ETWGLTP DYVLGHSVGE LAAAHVAGML CLADAVALVV atrif02a LFAVETALFR LF.ESWGVRP GLLAGHSIGE LAAAHVSGVL DLADAGELVA atmon03a LFALEVALYR QV.TSFGIAP SHLTGHSVGE IAAAHVAGVF SLADACTLVA atave12a LFAVQVALFR HL.ERLGVRA DFVAGHSIGE LAAAHVAGVL PLAAACRLVA atrif09a LFAVESALFR LA.ESWGVRP DVVLGHSIGE ITAAYAAGVF SLPDAARIVA atmon00a LFAIETSLYR LA.ASFGLKP DYVLGHSVGE IAAAHVAGVL SLPDASALVA atty103a LFALQTALFR LA.EHHGLRA EALCGHSVGE IAAAHAAGVL TLPDAARLVA

GHS

4/26 251 atave00x LWSQAQTT.L AGTGALVSVA ATPDELLPRI APWTEDN.PA RLAVAAVNGP LWSREMIP.L VGNGDMAAVA LSADEIEPRI ARWDDD.... .VVLAGVNGP atdebs00p RRSRLL.RRI SGQGEMALVE LSLEEAEAALRGHEG RLSVAVSNSP atepo06p RRSRLL.RRI SGQGEMALVE LSLEEAEAALRGHEG RLSVAVSNSP atepo07p atepo01p RRSRLL.RRI SGQGEMAVTE LSLAEAEAALRGYED RVSVAVSNSP atepo05p RRSLLL.RRI SGQGEMAVVE LSLAEAEAALLGYED RLSVAVSNSP AYGRII.RKL RGKGGMGLVA LSWEDAGKELTGYEG RLFRAIEHSA atsoralx atfkb01p LRSQAIAARL AGRGAMASIA VPASAVE.......TVE GVWIAARNGP atfkb09p LRSQTIAAHL AGRGAMASIA LPATAVE.....TVE GVWVAARNGP LRSQAIARGL AGRGAMASVA LPAQDVE.....LVD GAWIAAHNGP atrap03p LRSEAIARGL AGRGAMASVA LPAQDVE....LVD GAWIAAHNGP atrap06p LRSQAIARGL AGRAAMASVA LPAHEIE....LVD GAWIAAHNGP atrap04p LRSQAIARGL AGRGAMASVA LPAQDVE....LVD GAWIAAHNGP atrap13p LRSQVIARGL AGRGAMASVA LPAQDVE....LVD GAWVAARNGP atrap01p LRSQAIARGL AGRGAMASVA LPAHEIE....LVD GAWIAAHNGP atrap07p atrap10p LRSQAIARGL AGRGAMASVA LPAQDVE....LVD GAWIAAHNGP LRSALLVREL AGRGAMGSIA FAA..AA...RID GVWVAGRNGT atfkb04x LRAGLIGRYL AGRGAMAAVP LPAGEVEAGL AKWPG..... . VEVAAVNGP attyl04p LRAGLIGRYL AGRGAMAAVP LPAGEVEAGL AKWPG..... . VEVAAVNGP atty106p attyl01p LRAGLIGRYL AGRGAMAAVP LPAGEVEAGL AKWPG..... . VEVAAVNGP LRAGLIGRYL AGRGAMAAVP LPAGEVEAGL AKWPG..... . VQVAAVNGP attyl02p attyloop LRAGLIGRYL AGRGAMAAVP LPAGEVEAGL AKWPG..... . VEVAAVNGP atnidO5b LRSRAWLG.L AGKGGMVAVP MPAEELRPRLVTWGD RLAVAAVNSP atty105b LRSRAWLT.L AGKGGMAAVS LPEARLRERIERFGQ RLSVAAVNSP GRSRLWGR.L AGNGGMLAVM APAERIRELLEPWRQ RISVAAVNGP LRSRVIAT.M PGNKGMASIA APAGEVRARIGD RVEIAAVNGP atnid06x atdebs01p VRSDAL.RQL QGHGDMASLS TGAEQAAELI GDRPG......VVVAAVNGP atmon02p VRSDAL.RRL QGHGDMASLS TGAEQAAELI GDRPG......VVVAAVNGP atmon10p VRSDAL.ROL OGHGDMASLG TGAEQAAELI GDRPG..... .VVVAAVNGP atmon04p VRSDAL.ROL MGOGDMASLG ASSEOAAELI GDRPG......VCIAAVNGP atmon07p atmon11p VRSDAL.RQL QGHGDMASLS TGAEQAAELI GDRPG..... . VVVAAVNGP VRSDAL.RQL MGQGDMASLG AGSEQVAELI GDRPG..... .VCVAAVNGP atmon12p atmon05b VRSVLL.RQL SGRGGMASLG MGQEQAADLI DGHPG..... .VVVAAVNGP atmon01p LRSRAL.RQL SGGGAMASLG VGQEQAAELV EGHPG..... .VGIAAVNGP RRSRAV.RAV AGRGSMLSVR GGRSDVEKLL ADDS...WTG RLEVAAVNGP atdebs02p atdebs06p LRAKAL.RAL AGKGGMVSLA APGERARALI A..P...WED RISVAAVNSP LRSRALAA.V RGRGGMASVP LPAQEVEQLIGERWAG RLWVAAVNGP atave01p LRSRALAA.V RGRGGMASVP LPAQEVEQLIGERWAG RLWVAAVNGP atave07p LRSRALAA.V RGRGAMASLP LPAQDVQQLISERWEG QLWVAALNGP atave06p atave09p LRSQALAA.V RGRGAMVSLP LPAQDVQQLISERWEG QLWVAALNGP atnvs01p LRSQAIGRAL AGRGGMMSVA LSVDVLEPRL VE....FEG RVSVAAVNGP LRSQAIGRAL AGRGGMMSVA LSVDVLEPRL VE....FEG RVSVAAVNGP atnys11p atrifO5p LRSQAIAAEL SGRGGMASIQ LSHDEVAARL AP....WAG RVEIAAVNGP atrif07p LRSQAIAARL SGRGGMASVA LSEDEANARL GL....WDG RIEVAAVNGP LRSQAIAAKL AGRGGMASVA LSEEDAVARL RH....WAD RVEVAAVNSP atrif08p atrif10p LRSQAIAAKL SGRGGMASVA LGEADVVSRLAD GVEVAAVNGP atrif03p LRSQAIAGEL AGRGGMASVA LSEEDAVARL TP.....WAN RVEVAAVNSP LRSQAIATRL AGRGGMASVA LSEEDATAWL AP....WAD RVQVAAVNSP atrif06p LRSOAIAASL AGRGGMASVA LSEEDATARL EP....WAG RVEVAAVNGP atrif04p atrif01p LRSQAIAAEL SGRGGMASVA LGEDDVVSRLVD GVEVAAVNGP atnys02p LRSQALP.QL SGRGGMMSVS APVERVTALL AP.....WQE ALSVAAVNGP atfkb02p LRSRLVATER AGHGGMVSVP PADFDAAA......WAG RLEVAAVNGP atave11p LRSOALA.AL AGOGAMASVG LPVEKLEPRL A....TWGD RLVIAAVNGA GRSRLM.RSL SGEGGMAAVA LGEAAVRERL RPWQ.....D RLSVAAVNGP atdebs03p LRSQLIAREL AGRGSMASVA LAAADVESRL AGAEAGGGVR DVEIAAVNGP atnid04p VRSRVL.RRL GGQGGMASFG LGTEQAAERIGRFAG ALSIASVNGP atdebs05p atdebs04p LRSQVL.REL DDQGGMVSVG ASRDELETVL A....RWDG RVAVAAVNGP

5/26 atave02a atave05a ----- ----- ------ -------atrap05a ----- ----- ------ ------ -------atfkb08x ----- ----- ----- ------ ------atnid03a ----- ---- ----- ----- ------ ------atmon06a ----- ----- ------atmon08a atmon09a atepo02a atepo03x atepo08a atty107a ~~~~~LR DHLSRTPGAR atsor02a ------ ------ ------- ------atsorbla ----- ----- ------ ------ ------atnys09a ********************************* atnys16a atnys07a ------ ----- ------ ------ -------atnys05a atnys06a atnys04a atnys14a atnys00a atnys10a atnys18a atave12a atrif09a atmon00a atty103a SVPAGEPPAA GRPEDTGGAW TVSGRGPAAL RAQAARLYDA LTGTGTGTGQ

6/26								
	51				100			
atave00x	~~~~~~~	~~~~~~	~~~~~~~	~~~~~VQR	MDGGEEPRPA			
atdebs00p	~~~~~~	~~~~~~	~~~~~~~	~~~~~~	~~~VADGRPH			
atepo06p	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~	~~AAAQGHTP			
atepo07p	~~~~~~~	~~~~~~	~~~~~~~	~SSREALRGA	LSAAAQGHTP			
atepo01p	~~~~~~~	~~~~~~	~~~~~~~	~~~~~REG	LDAAARGQTP			
atepo05p	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~	~~~~~P			
atsora1x	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~~			
atfkb01p	~~~~~~~	~~~~~~	~~~~~~~	~~~~~~	~~~~~~			
atfkb09p	~~~~~~~	~~~~~~	~~~~~~	~~~~~~	~~~~~~			
atrap03p	SAKTQPALTE	HEDRLRAYLA	ASPGADTRAV	ASTLAVTRSV	FEHRAVLLGD			
atrap06p	~~~TQPALTE	HEDRLRAYLA	ASPGVDTRAV	ASTLAVTRSV	FEHRAVLLGD			
atrap04p		HEDRLRAYLA			FEHRAVLLGD			
atrap13p		HEDRLRAYLA		ASTLAVTRSV	FEHRAVLLGD			
atrap15p	~~~~~~~	~~~~~~~		~~~LAVTRSL	FEHRAVLLGD			
atrap01p		HEDRLRAYLA			FEHRAVLLGH			
	~~~~~~~~		~~~~~~AV		FEHRAVLLGD			
atrap10p		~~~~~~~		ADILIAVINOV	~~~~~~~			
atfkb04x								
atty104p		GEAELAGRLR			• • • • • • • • • •			
atty106p		GEAELAGRLR			• • • • • • • • • •			
atty101p		GEAELAGRLR			• • • • • • • • • •			
atty102p	~~~~~~	~~~~RLR	ALAGGDPDAG	VVTGAVVD	• • • • • • • • •			
atty100p	FGYRAVVLAR	GEAELAGRLR	ALAGGDPDAG	VVTGAVLDGG	VVVGAAPGGA			
atnid05b	~~~~~~	~~~~LLSTR	ARFPRRAAVV	GESMTELAEA	LDAVAEGGPH			
atty105b	LLEHPDEHPA	DVGYTLITGR	AHFGHRAAVI	GESREELLDA	LKALAEGREH			
atnid06x	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~RSVAEERPE			
atdebs01p	~~~~~~	~~~~~~	~~~~~~	~~~~~~	~~GLATGNAD			
atmon02p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~GALAAGEAS			
atmon10p	~~~~~~	~~~~~~	~~~~~~~	~~~~~~	LGALAAGEAS			
atmon04p	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~~LAAGETP			
atmon07p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~~ALAAGEES			
atmon11p	~~~~~~	~~~~~~~	~~~~~~	~~~~~~~	~~ALAAGEAS			
atmon12p	~~~~~~	~~~~~~	~~~~~~	~~~~~~	~~~LAAGEPS			
atmon05b	~~~~~~	~~~~~~	~~~~~~	~~~~~~~	~~SLAAGEAS			
atmon01p	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~EALAAGDAS			
atdebs02p	~~~~~~	~~~~~~	~~~~~~	~~~~~~	~~~~ADGAVV			
_	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~~	~RAVAEGVAA			
atdebs06p	~~~~~~~	~~~~~~~~	~~~~~~~	~~~~~~G	LGALAAGEPD			
atave01p	~~~~~~~	~~~~~~~	~~~~~~~	~~~~~~G				
atave07p		~~~~~~~		_	LGALAAGEPD			
atave06p	~~~~~~		~~~~~~	_	LTALAAGEPH			
atave09p	~~~~~~	~~~~~~	~~~~~~	~~~~~~	LTALAAGEPH			
atnys01p	~~~~~~	~~~~~~	~~~~~~~	~~~~~~	~~~~~~~			
atnys11p	~~~~~~	~~~~~~		~~~~~~	~~~~AVATDG			
atrif05p	~~~~~~	~~~~~~		~~~~~~	~TALARGESA			
atrif07p	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~G	LGALARGEAA			
atrif08p	~~~~~~	~~~~~~			LAALARGESA			
atrif10p	~~~~~~	~~~~~~~	~~~~~~~	ADSAEEARAG	LGALARGEDA			
atrif03p	~~~~~~	~~~~~~~	~~~~~~~	~~~~~QDG	LQALARGENA			
atrif06p	~~~~~~	~~~~~~~	~~~~~~	~~SREEAVTN	LEALARGEDP			
atrif04p	~~~~~~	~~~~~~~	~~~~~~~	~~~~~~	~RALARGESA			
atrif01p	~~~~~~~	~~~~~~~	~~~~~~~		VVAGSREEAV			
atnys02p	~~~~~~			GERREDFLRG				
atfkb02p	~~~~~~	~~~~~~~			~~~~~GEEV			
•	~~~~~~~				LDALAEGAPT			
atave11p	~~~~~~		~~~~~~~					
atdebs03p					~~~~~AATA			
atnid04p		AGIGHGLAVG						
atdebs05p	~~~~~~	~~~~~~		~~~~~~	~~~~ADRRIA			
atdebs04p	~~~~~~~	~~~~~~~	~~~~~~~~	~~~~~~	~~ALAEGRPS			

			- <del>-</del>		
atave02a				~~~~~~	
atave05a	~~~~~~~	~~~~~~	~~~~~~~	~~~~QALQAL	AAGEPHPAVI
atave04a	~~~~~~~	~~~~~~~	~~~~~~	~~~~QALQAL	AAGEPHPAVI
atave08a	~~~~~~~	~~~~~~	~~~~~~	~~~~QALQAL	AAGEPHPAVI
atave03a	~~~~~~~	~~~~~~	~~~~~~	~~~~QALQAL	AAGEPHPAVI
atrap02a	~~~~~~~	~~~~~~	~~~~~DT	RAVASTLAMT	RSVFEYRAVL
atrap11a	~~~~~~~	~~~~~~~		~AVASTLAMT	
atrap08a	MVISARTQSA	LTEHEGRLRA	YLAASPGVDM	RAVASTLAIT	RSVFEHRAVL
atrap12a	~~~~~~~	LTEHEGRLRA	YLAASPGVDM	RAVASTLAMT	RSVFEHRAVL
atrap05a	~~~~~~~	~~~~~~	~~~~~~	~~~ASTLAVT	RSVFEHRAVL
atrap09a	LVISAKTQSA	LAEYEGRLRA	YLAASPGVDM	RAVASTLAMT	RSVFEHRAVI
atfkb03a	~~~~~~~	~~~~~~~	~~~~~~	~~~~~~	~~~~HRAAL
atfkb07x	~~~~~~~	~~~~~~	~~~~~~	~~~~~~	~~~~~L
atfkb08x	~~~~~~~			~~~~~~	
atnid01a	~~~~~~~	~~~~~~	~~~~KHRA	VITGRTRTEL	HTKLHTLDAI
atnid03a	~~~~~TQA			VITGRTRTEL	
atnid02a	~~~~~~~	~~~~~HALA	TTCTHFKHRA	VITGRTRTEL	HTKLHTLDAI
atnid00a	~~~~~~~	~~~~~~	~~~~~~	~~~~~~~	SSALAALAAG
atfkb10a				~~~~~~	
atrap14a	~~~~~~~			~~~~DFLRA	
atmon06a	~~~~~~			~~~~~~~	
atmon08a	~~~~~~			~~~~~~~	~~~~AGEEHP
atmon09a		~~~~~~			~~~~GEEHP
atepo02a	~~~~~~~			~~~~~~	AALSAVAQGQ
atepo03x	~~~~~~~	~~~~~~	~~~~~A	VAVTSREGLL	AALSAVAQGQ
atepo08a	~~~~~~	~~~~~~	~~~~~~~	~~~~~~~	~~~~VAAQGQ
atepo00a	~~~~~~~	~~~~~~	~~~~~~	~~~~SREGLR	AALDAAAQGQ
atepo04a	~~~~~~	. ~~~~~~~	~~~~~~~	~~~~~LR	GALDAAAQQK
atnid07a	~~~~~~	~~~~~~	~~~~~A	AAHDALLAVA	DGRPSDAVVT
attyl07a				AALDALA	
atsor02a	~~~~~~			~~~~~~~	
atsorbla	~~~~~~~			~~~~~~	~~~~~~
atnys09a		~~~~~~			DPAAAPAWIT
atnys12a	~~~~~~~		~~~~~~	_	DGRPDPGLVQ
atnys16a		~~~~~~			~PD.LPEVAR
atnys17a	~~~~~~	~~~~~~~			APDGITAAAR
atnys03a		~~~~~~			PDGTELAH
atnys15a	~~~~~~~	~~~~~~			PDAHE.GH
atnys07a	~~~~~~	~~~~~~	~~~~~~	~~~~~IAA	DEA.DAAAAT
atnys08a	~~~~~~	~~~~~~	~~~~~~	~~~ALAALAS	GVA. DPAVVS
atnys05a	~~~~~~	~~~~~~	~~~~~~~	AVRALTALAA	ADA.DLSAVV
atnys06a	~~~~~~	~~~~~~	~~~~~~	ATRALSALAT	TAASDPSALT
atnys04a	~~~~~~	~~~~~HR	AVVLGTDRAE	ALRALTALAA	GE.TDPAALT
atnys14a				LRTGLTAVAE	
atnys00a				~~~~~~~	
atnys10a				LIASLGALAA	
atnys18a				~~~~~~~~	
atnys13a				~~~~~LLA	
atave10a				~~LHALDALA	
atrif02a	~~~~~~	~~~~~~	~~~~~R	AVVLASDRAQ	LCADLAAFGS
atmon03a	~~~~~~~	~~~~~~~	~~~~~~	~~~~~A	LAAGRAHPAL
atave12a	~~~~~~	~~~~~~	~~~~~~	~~~QALDALA	EGRSADGLIE
atrif09a				AVVVAGTDED	
atmon00a				~~~~~~~~	
attyl03a	GAGQGAGPGT	AEVAGALAHA	RTAFRHRAVV	LGGNRAELLA	GLRELAEEEH

8/26 101 ataveOOx AGEVLGVADE ADGG..VVFV FPGQGPQWPG MGRELLDASD VFRESVRACE atdebs00p ASVVRGVA.R PSAP...VVFV FPGQGAQWAG MAGELLGESR VFAAAMDACA PGAVRGRASG GSAP.KVVFV FPGQGSQWVG MGRKLMAEEP VFRAALEGCD atepo06p PGAVRGRASG GSAP.KVVFV FPGQGSQWVG MGRKLMAEEP VFRAALEGCD atepo07p atepo01p PGAVRGRCSP GNVP.KVVFV FPGQGSQWVG MGRQLLAEEP VFHAALSACD atepo05p PAAARGHAST GSAP.KVVFV FPGQGSQWLG MGQKLLSEEP VFRDALSACD ~~~~~~~~ ~~~~~VFV FAGQGAQWFG MGRALLQREP VFRTTIEQCS atsora1x atfkb01p ~~~~SAVAGV AVEGARTVFV FPGQGSQWVG MGRELMGASE VFAARMRECA atfkb09p ~~~~~~~~~~~VFV FPGQGSQWVG MGRELMGCSE VFAARMRECA atrap03p D..TV..TGT AVSDPRVVFV FPGQGWQWLG MGSALRDSSV VFAERMAECA atrap06p D..TV..TGT AVSDPRVVFV FPGQGWQWLG MGSALRDSSI VFAERMAECA atrap04p D..AV..TGT AVTDPRVVFV FPGQGWQWLG MGSALRDSSV VFAERMAECA atrap13p D..TV..TGT AVTDPRIVFV FPGQGWQWLG MGSALRDSSV VFAERMAECA atrap01p D..SVTGTGT AVSDPRVVFV FPGQGWQWLG MGSALRTSSM VFAERMAECA atrap07p DTVTVTGTGT AVSNPRVVFV FPGQGWQWLG MGSALRGSSV VFAERMAECA atrap10p ETV....TGT AVSDPRIVFV FPGQGWQWLG MGSALRDSSV VFAERMAECA atfkb04x ~~~~VVTGT ALTAPRTVFV FPGQGSQWLG MGRELMAESP VFAARMRQCA atty104p .....PET GSGGGGVVLV FPGQGTQWVG MGAGLLGSSE VFAASMRECA .....PET GSGGGGVVLV FPGQGTQWVG MGAGLLGSSE VFAASMRECA atty106p .....PET GSGGGGVVLV FPGQGTQWVG MGAGLLGSSE VFAASMRECA atty101p .....PET GSGGGGVVLV FPGQGTQWVG MGAGLLGSSE VFAASMRECA atty102p attyl00p GAAGGAGAAG GAGGGGVVLV FPGQGTQWVG MGAGLLGSSE VFAASMRECA atnidO5b ..PLAATGT. AGTADRVVFV FPGQGSQWAG MAEGLLERSG AFRSAADSCD atty105b HTVVRGDGT. AHPDRRVVFV FPGQGSQWPS MARDLLDRAP AFRETAKACD atnid06x PDVVL..GE. AGSDRAPAFV FPGQGAQWAG LGARLLADSP VFRARAEACA atdebs01p GAAV...GT. SRAQQRAVFV FPGQGWQWAG MAVDLLDTSP VFAAALRECA atmon02p AGVVAG.VAG DVGPGP.VLV FPGQGAQWVG MGAQLLDESA VFAARIAECE atmon10p AGVVAG.VAG DVGPGP.VLV FPGQGSQWVG MGAQLLDESP VFAARIAECE atmon04p TDVVSG.AAA SSGAGP.VLV FPGQGSQWVG MGAQLLDESP VFAARIAECE atmon07p ADVVAG.VAG DVGPGP.VLV FPGQGSQWVG MGAQLLDESP VFAARIAECE atmon11p ADVVAG.VAG DVGPGP.VLV FPGQGSQWVG MGAQLLDESP VFAARIAECE atmon12p PDVVEGAVOG ASGAGP.VLV FPGQGSQWVG MGAQLLDESP VFAARIAECE atmon05b PDVVSGAV.G PTGPGP.VMV FPGQGGQWVG MGARLLDESP VFAARIAECE atmon01p PDVVCG.VAG DVGPGP.VLV FPGQGSQWVG MGAQLLGESA VFAARIDACE atdebs02p PGVVTGSASD ....GGSVFV FPGQGAQWEG MARELL.PVP VFAESIAECD atdebs06p PGATTGTASA ....GGVVFV FPGQGAQWEG MARGLL.SVP VFAESIAECD RRVTTGHAPG GDRGG.VVFV FPGQGGQWAG MGVRLLASSP VFARRMQACE atave01p atave07p RRVTTGHAPG GDRGG.VVFV FPGQGGQWAG MGVRLLASSP VFARRMQACE atave06p PHITTGHTRG GDRGG.VVFV FPGQGGQWAG MGLTLLTSSP VFAEHIDACE atave09p PHITTGHTRG SDRGG.VVFV FPGQGGQWAG MGLTLLTSSP VFAEHIDACE atnys01p ~~~~~L. ADVEGRTVFV FPGQGSQWVG MGAQLLDESA VFAERIAECA atnyslip PSPVVARGV. ADVEGRTVFV FPGQGSQWVG MGSQLLDESA VFAERIAECA atrif05p SGLVTGT... AGMPGKTVWV FPGQGTQWAG MGRELLEASP VFAERIEECA atrif07p PGVVTGT... AGKPGKVVWV FPGQGTQWVG MGRELLDASP VFAERIKECA atrif08p ADVVTGTVAA SGVPGKLVWV FPGQGSQWVG MGRELLEASP VFAARIAECA atrif10p PGLVRGRVPA SGLPGKLVWV FPGQGTQWVG MGRELLEESP VFAERIAECA atrif03p PGVVTGT... AGKPGKVVWV FPGQGSQWMG MGRDLLDSSP VFAARIKECA atrif06p AAVVTGR... AGSPGKLVWV FPGQGSQWIG MGRELLDSSP VFAERVAECA atrif04p PGLLSGR..G SGVPGKVVWV FPGQGTQWAG MGRELLDSSE VFAARIAECE atrif01p TGLRALNTAG SGTPGKVVWV FPGQGTQWAG MGRELLAESP VFAERIAECA atnys02p AGLVSG..IA GPDPEGAVFV FPGQGSQWWG MGRELLATSE VFRTAIDDCA atfkb02p PGVVRGTADV TDT..RAVFV FPGQGSQWDG MGAELLATEP VFARRLGECA atavellp AGVVQGVAGP AA.DGKIAML FGGQGTHWEG MAQELLGSSP VFAQQMSDCA atdebs03p DAVVEGV.TE VD.GRNVVFL FPGQGSQWAG MGAELLSSSP VFAGKIRACD atnid04p PDVVTG..SA AD.VRRVAFV FPGQGAQWAG MGAELLDSSP VFAAELARCE atdebs05p DRTATGQ.GP NS.PRRVAMV FPGQGAQWQG MARDLLRESQ VFADSIRDCE atdebs04p ADAVAPVTSA ...PRKPVLV FPGQGAQWVG MARDLLESSE VFAESMSRCA

Fig 2e

## 9/26

•		•			
atave02a		GEAAGKTAFI			
atave05a		GEAAGKTAFI			
atave04a		GEAAGKTAFI			
atave08a	HSSAPGGTGT	GEAAGKTAFI	CSGQGTQRPG	MAHGLYHTHP	VFAAALNDIC
atave03a	HSSAPGGTGT	GEAAGKTAFI	CSGQGTQRPG	MAHGLYHTHP	VFAAALNDIC
atrap02a	IGDDTVTG.T	AATDPRVVFV	FPGQGSQRAG	MGEELAAAFP	VFARIHQQVW
atrap11a		AVSDPRVVFV			VFARIHQQVW
atrap08a		AATDPRVVFV			VFARIHQQVW
atrap12a		AVSDPRAVEV			VFARIHQQVW
atrap05a		TVSDPRVVFV			VFARIHQQVW
atrap09a		AATDPRVVFV			VFARIHQQVW
atfkb03a		AEPDRRLVWL			VFARTRRDVL
atfkb07x		NAGSGPVVFV			
atfkb08x		ADQADELVFV			
atnid01a		AHPHPRLTLL			
atnid03a		AHPHPRLTLL			
atnid02a		AHPHPRLTLL			
atnid00a		TDADGRLALL			
atfkb10a		EPPRSARRFL			
atrap14a		KARRVAFL			
atmon06a		${\tt RVGGDDVVWL}$			
atmon08a		AASG.AVVWL			
atmon09a		VAASGDVVWL			
atepo02a		SSSRGKLAFL			
atepo03x		SSSRGKLAFL			
atepo08a		ASSPGKLAFL			
atepo00a		DSSRGKLAFL			
atepo04a		VSSRGKLAFL			
atnid07a		RGRDVAFL			
attyl07a	GVRD	RDGRMAFL	FTGQGSQRAG	MAHDLHAAHT	FFASALDEVT
atsor02a	~~~~~~	~~~~~AVL	FTGQGSQRPT	MGRALYDAFP	VFRDALDTVA
atsorb1a		~~~~~AIL			
atnys09a		AETRLAVL			
atnys12a	GTA		FTGQGSQRPG		
atnys16a	GAA.TPH		FSGQGAQRSG		
atnys17a atnys03a	AEA.RER		FSGQGAQRSG		
atnysusa atnys15a	GTA.GEG		FSGQGSQRPG		
	.AA.GRT GRV.GAG		FSGQGAQRLG FSGQGAQRLG		
atnys07a	DAV.STG				
atnys08a atnys05a			FTGQGAQRLG FSGOGSORLG		
atnys05a atnys06a	GDT.RTG GTV.TMG		FSGQGSQRLG		
atnys04a	GTV.RTG		FSGQGSQRLG		
atnys04a	HLQ.GTG		FSGQGSQRLG		
atnys14a				•	
atnystoa atnys10a		RTAVL			
atnys18a		RTAVL			
atnys13a		DRGGLAVL			
atave10a		P.GRTAFL			
atavelua atrif02a		ELAVL			
atmon03a		VDGKLAVL			
atave12a		RNGGTAFL			
atavelza atrif09a		GRRRGKTAML			
atmon00a		SAKHGKVVYV			
attyl03a		AYTEGRTAFL			
accarosa	EGEKAAIGIA	PATERRTAFL	PHYTOSTANG	POWOTIVKUS	O A THRALLUE V C

GQG

10/26 200 atave00x AAFAPYVDWS VEQVLRDSPD A......PG LDRVDVVQPT atdebs00p RAIEAEAGWS LLGEL..... SA..... DEAASQ LGRIDVVQPV atepo06p atepo07p RAIEAEAGWS LLGEL..... SA..... DEAASQ LGRIDVVQPV RAIQAEAGWS LLAEL..... AA...... DEGSSQ LERIDVVQPV atepo01p atepo05p RAIQAEAGWS LLAEL.....AA.......DETTSQ LGRIDVVQPA atsoralx SFIQONLGWS LLDEL.... .MT..... DRESSR LDEIDVSLPA atfkb01p AVLEPHTGWD LLDVL..... ......GEAVV VDRVEVLQPA atfkb09p AVLEPYTGWD LLDVL..... ......GEAVV AERVEVLQPA atrap03p AALSEFVDWD L.TVL..... ......DDPAV VDRVDVVQPA atrap06p PALREFVDWD LFTVL..... ......DDPAV VDRVDVVQPA atrap04p AALSEFVDWD LFAVL..... ......DDPAV VDRVDVVQPA atrap13p AALREFVDWD LFTVL..... DDPAV VDRVDVVQPA atrap01p AALSEFVDWD LFAVL..... DDPAV VARVDVVQPA atrap07p AALSEFVDWD LFAVL......DDPAV VDRVDVVQPA atrap10p AALSEFVDWD LFAVL..... DDPAV VDRVDVVQPA atfkb04x DALAEHTGRD LIAML..... DDPAV KSRVDVVHPV atty100p RALSVHVGWD LLEVVSG.......GAG LERVDVVQPV atnid05b AALRPYLGWS VLSVLRGEPD ......APS LDRVDVVOPV AALRPYLGWS VLSVLRGEPD ......APS LDRVDVVQPV atty105b AALSVHLDWS VLDVLQEKPD ......APP LSRVDVVQPV atnid06x RALEPHLDWS VLDVLAGAPG ..........TPP IDRADVVQPV atdebs01p DALEPHLDFE VIPFLRAEAA RRE......QDAALS TERVDVVQPV atmon04p QALSAYVDWS LSDVLRG..D .......GSE LSRVEVVQPV RALSAHVDWS LSAVLRG..D ......GSE LSRVEVVQPV atmon12p atmon05b QALSAYVDWS LTDVLRG..D .......GSE LARIDVVQPV atdebs02p AVLSEVAGFS VSEVLEPRPD .........APS LERVDVVQPV atdebs06p AVLSEVAGFS ASEVLEQRPD ......APS LERVDVVQPV ataveOlp EALAPWVDWS VVDILRRDAG .........DAV WERADVVQPV atave07p EALAPWVDWS VVDILRRDAG .......DAV WERADVVQPV atave06p KALTPWVPWS LTDILHRDPD ..........DPA WQQADVVQPV atave09p KALTPWVPWS LTDILHRDPD .......DPA WQQADVVQPV atnys01p AALAEFTDWS LVDVLRGVVG .......APS LERVDVVQPA atnys11p AALAEFTDWS LVDVLRGVVG .......APS LERVDVVQPA atrifO5p AALQPWIDWS LLDVLRG..E ......GE. LDRVDVLQPA atrif03p AALEQWTDWS LLDVLRG..D .......ADL LDRVDVVQPA atrif06p AALEPWIDWS LLDVLRG..E ......SDL LDRVDVVQPA átrif04p TALGRWVDWS LTDVLRG..E ......ADL LDRVDVVQPA atfkb02p EALAPYTGWD LLDVIARRPG ......APE LDRVDVVQPA atavellp QALEPYLDWS LLDVLRGAPD ......APP LQRVDVVQPV atdebs03p ESMAPMQDWK VSDVLRQAPG ......APG LDRVDVVQPV atnid04p AALEPFVDWS LTDVLRGAPG .......APG LDRVDVVQPV atdebs05p RALAPHVDWS LTDLL...SG .......ARP LDRVDVVQPA

atdebs04p EALSPHTDWK LLDVVRGDGG .......pdp HERVDVLQPV

11/26 atave02a THLDPHLDHP LLPLLTQ..N DNDN..... EDAAAL LQQTRYAQPA atave05a THLDPHLDHP LLPLLTQNDN DNDN..... EDAAAL LQQTPYAQPA atave04a THLDPHLDHP LLPLLTQDPN TQDT..... TTLEEAAAL LQQTPYAQPA atave08a THLDPHLDHP LLPLLTQDPN TQDT..... TTLEEAAAL LQQTPYAQPA atave03a THLDPHLDHP LLPLLTQDPN TQDT..... .TTLEEAAAL LQQTRYAQPA atrap02a DLLDVP.DLD ...... VNETGYAQPA atraplla DLLDVP.DLD ...... VNETGYAQPA atrap08a DLLDVP.DLE ...... VNETGYAQPA atrap12a DLLDVP.DLE ...... VNETGYAQPA atrap05a GLLDVP.DLE ...... VNETGYAQPA atrap09a DLLDVP.DLE ...... VNETGYAQPA atfkb03a DALQVPAGLD ..... VHDTGYAQPA atfkb07x GHLN..ADQG ..... P.....AT atfkb08x RRLD...DPD ...... PHDPTRSQHT EELQR..... C GTQNLREVMF TPD...QPDL LDRTEYTQPA atnid01a EELQR..... GTQNLREVMF TPD...QPDL LDRTEYTQPA atnid03a atnid02a EELQR..... GTQNLREVMF TPD...QPDL LDRTEYTQPA atnid00a EELQR..... GTQNLREVMF TPD...QPDL LDRTEYTQPA atmon06a GLLEGPL.........GV EAGGLREVVF RGPR....ER LDHTVWAQAG atmon08a GLLEGPL... ........GV EAGGLREVVF RGPR....ER LDHTMWAQAG atmon09a GLLEGEL.........GV GSGGLREVVF WGPR....ER LDHTVWAQAG atepo02a ALFDRELDRP ......LREVMW AEAGSAESLL LDQTAFTQPA atepo03x ALFDRELDRP ......LREVMW AEPGSAESLL LDQTAFTQPA atepo08a TLFDRELHQP ......LCEVMW AEPGSSRSSL LDQTAFTQPA atepo00a RLFNQELDRP ...... LREVMW AEPASVDAAL LDQTAFTQPA atepo04a ALFDREIDQP .........LREVMW AAPGLAQAAR LDQTAYAQPA atnid07a GGFDAHLERP .....LLQVMF AEPGTADAAL LDRTAYAQPA atty107a DRLDPLLGRP .....LGALLD ARPGSPEAAL LDRTEYTQPA atsor02a AHLDRDLDRP .....LRDVLF APDGSEQAAR LDQTAFTQPA atsorbla AHLDRDLDRP .....LRDVLF APDGSEQAAR LDQTAFTQPA atnys09a DAFTPHLDRP ......LREVLW ....GTDAAL LDRTAYAQPA atnys12a ARLDDGPDRP ......LREVLF AAPDSAEAAL LDRTGYAQPA atnys16a AVLDAELGSD ......AD GGVSLREVMW GGG....SEL LDRTRFTQPA atnys17a AVLDAELATG ......SG GGVSLREVMW GGG....SEL LDRTRFTQPA atnys03a ALLDTHLDRP ......LREVVW GTD....ADL LNDTGWAQPA DLLDAELGGT .....LREVIW GTD....DAP LNETGFTQPA atnys15a DHLDAALPAQ .....AG ....LREVMW GDD....AEL LNETGWTQPA atnys07a DHLDAALPAQ .....AG ....LREVMW GDD....VEL LNETGWTQPA atnvs08a DHLDAALPAQ ......AS ....LREVMW GDD....VEL LDETGWTQPA atnys05a DHLDAALPAQ .....AG ....LREVMW GDD....VEL LNETGWTQPA atnvs06a atnys04a TALDAELGHP ..........LRDIIW GED....AQL VDRTGYTQPA atnys14a ARLDDRLDTP ......LRDVVW GTD. .EEA LHATGNTQPA atnys00a RALDRHLDGP ...........VREVMW GTD....AAL LDRTGWTQPA atnys10a AVFDPLLDRP ......LREVVF AEDGSDEAAL LDETGWTQPA atnys13a AQFDTVLDVP ..........LRAALF AAPGTPEAAL LDQTGFTQPA atave10a AEADTARTDP ......GA PG..LRDVLF APQDSPEGRL IEDTGFAQPA atrif02a EAVDTHL... RERPLREVVF .....DDSAL LDQTMYTQGA atmon03a ARLDPLLEQP ......LKPVLF APADTAQAAV LHGTGMTQAA atave12a AELDGHLDQP ......LR PLIHASADL. .ADVADAADV LDRTRYAQPA atrif09a EQLDVCL..A ......GR AGHRVRDVVL GE.VPAETGL LNQTVFTQAG atmon00a AALDVHLDRP LREIVLGETD SGGNVSGENV IGEGADHQAL LDQTAYTQPA atty103a AALEPHLHRP .....LRDLMF AEPGSPEAEP LDRTEFTQPA

12/26 201 atave00x LFAVMISLAA L.WRSQGVEP CAVLGHSLGE IAAAHVSGGL SLADAARVVT atdebs00p LFAVQTSLAA L.WRSFGVTP DAVVGHSIGE LAAAHVCGAA GAADAARAAA atepo06p LFAMEVALSA L.WRSWGVEP EAVVGHSMGE VAAAHVAGAL SLEDAVAIIC atepo07p LFAMEVALSA L.WRSWGVEP EAVVGHSMGE VAAAHVAGAL SLEDAVAIIC atepo01p LFALAVAFAA L.WRSWGVAP DVVIGHSMGE VAAAHVAGAL SLEDAVAIIC atepo05p LFAIEVALSA L.WRSWGVEP DAVVGHSMGE VAAAHVAGAL SLEDAVAIIC atsoralx IISIEIALAA Q.WRAWGVEP AFVVGHSTGE IAAAHVAGVL SIEDAMRTIC atfkb01p SWAVAVSLAA L.WQAHGVVP DAVVGHSQGE IAAACVAGAL SLEDAARVVA atfkb09p SWAVAVSLAA L.WQAHGVSP DAVIGHSQGE IAAACVAGAL SLEDAARIVA atrap03p SWAVMVSLAA V.WQAAGVRP DAVIGHSQGE IAAACVAGAV SLRDAARIVT atrap06p SWRMMVSLAA V.WQAAGVRP DAVIGHSQGE IAAACVAGAV SMRDAARIVT atrap04p SWAVMVSLAA V.WQAAGVRP DAVIGHSQGE IAAACVAGAV SLRDAARIVT atrap13p SWAMMVSLAA V.WQAAGVRP DAVIGHSQGE IAAACVAGAV SLRDAARIVT atrap01p SWAVMVSLAA V.WQAAGVRP DAVVGHSQGE IAAACVAGAV SLRDAARVVT atrap07p SWAVMVSLAA V.WQADGVRP DAVIGHSQGE IAAACVAGAV SLRDAARSVT atrap10p SWAVMVSLAA V.WQAAGVRP DAVIGHSQGE IAAACVAGAV SMRDAARIVT atfkb04x CWAVMVSLAA V.WEAAGVRP DAVVGHSQGE IAAACVAGAI SLEDGARLVA attyl04p TWAVMVSLAR Y.WQAMGVDV AAVVGHSQGE IAAATVAGAL SLEDAAAVVA attyl06p TWAVMVSLAR Y.WQAMGVDV AAVVGHSQGE IAAATVAGAL SLEDAAAVVA attyl01p TWAVMVSLAR Y.WQAMGVDV AAVVGHSQGE IAAATVAGAL SLEDAAAVVA atty102p TWAVMVSLAR Y.WQAMGVDV AAVVGHSQGE IAAATVAGAL SLEDAAAVVA atty100p TWAVMVSLAR Y.WQAMGVDV AAVVGHSQGE IAAATVAGAL SLEDAAAVVA atnid05b LFTMMVSLAA V.WRALGVEP AAVVGHSQGE IAAAHVAGAL SLDDSARIVA atty105b LFTMMLSLAA C.WRDLGVHP AAVVGHSQGE IAAACVAGAL SLEDAARIVA atnid06x LFTTMVSLAA L.WEAHGVRP AAVVGHSQGE VAAACVAGAL SLDDAALVIA atdebs01p MFAVMVSLAS M.WRAHGVEP AAVIGHSQGE IAAACVAGAL SLDDAARVVA atmon02p LWAVMVSLAA V.WADYGVTP AAVIGHSQGE MAAACVAGAL SLEDAARIVA atmon10p LWAVMVSLAA V.WADYGVTP AAVIGHSQGE MAAACVAGAL SLEDAARIVA atmon04p LWAVMVSLAA V.WADYGVTP AAVVGHSQGE MAAACVAGAL SLEDAARIVA atmon07p LWAVMVSLAA V.WADYGVTP AAVIGHSQGE MAAACVAGAL SLEDAARVVA atmon11p LWAVMVSLAA V.WADYGITP AAVIGHSQGE MAAACVAGAL SLEDAARIVA atmon12p LWAVMVSLAS V.WADYGITP AAVIGHSQGE MAAACVAGAL SLEDAARIVA atmon05b LWAVMVALAA V.WADQGIEP AAVVGHSQGE IAAACVVGAI SLDEAARIVA atmon01p LWAVMVSLAA V.WADHGVTP AAVVGHSQGE IAAVVVAGAL TLEDGAKIVA atdebs02p LFAVMVSLAR L.WRACGAVP SAVIGHSQGE IAAAVVAGAL SLEDGMRVVA atdebs06p LFSVMVSLAR L.WGACGVSP SAVIGHSQGE IAAAVVAGVL SLEDGVRVVA ataveOlp LFSVMVSLAA L.WRSYGIEP DAVLGHSQGE IAAAHVCGAL SLKDAAKTVA atave07p LFSVMVSLAA L.WRSYGIEP DAVLGHSQGE IAAAHVCGAL SLKDAAKTVA atave06p LFSIMVSLAA L.WRSYGIEP DAVLGHSQGE IAAAHICGAL SLKDAAKTVA atave09p LFSIMVSLAA L.WRSYGIEP DAVLGHSQGE IAAAHICGAL SLKDAAKTVA atnys01p SFAVMVSLAA L.WGSRGVLP DAVVGHSQGE IAAAVVSGAL SLRDGARVVA atnys11p SFAVMVSLAA L.WRSRGVLP DAVVGHSQGE IAAAVVSGAL SLRDGARVVA atrif05p CFAVMVGLAA V.WASVGVVP DAVLGHSQGE IAAACVSGAL SLEDAAKVVA atrif07p CFAVMVGLAA V.WESAGVRP DAVVGHSQGE IAAACVSGAL TLDDAAKVVA atrif08p SFAVMVGLAA V.WSSVGVVP DAVLGHSQGE IAAACVSGAL SLQDAAKVVA atrif10p CFAVMVGLAA V.WSSAGVVP DAVLGHSQGE IAAACVSGAL SLEDAAKVVA atrif03p SFAMMVGLAA V.WTSLGVTP DAVLGHSQGE IAAACVSGAL SLDDAAKVVA atrif06p SFAMMVGLAA V.WQSVGVRP DAVVGHSQGE IAAACVSGAL SLQDAAKVVA atrif04p SFAVMVGLAA V.WASLGVEP EAVVGHSQGE IAAACVSGAL SLEDAAKVVA atrif01p CFAVMVGLAA V.WESVGVRP DAVVGHSQGE IAAACVSGAL SLEDAAKVVA atnys02p LFAMMVGLSA L.WRSHGVVP AAVVGHSQGE IAAACVAGAL SLADAARVVA atfkb02p SFAMMVALAE L.WRAHGVAP AAVVGHSQGE VAAACVAGVL TLDDAAKVVA atavellp LFAVMVSLAA L.WRSYGVHP DAVAGHSQGE IAAAYVAGAL SLDDAARVTA atdebs03p LFAVMVSLAE L.WRSYGVEP AAVVGHSQGE IAAAHVAGAL TLEDAAKLVV atnid04p TFAVVVALAA M.WRWLGVEP AAVVGHSQGE IAAAHVAGVL SLEDAARVVA atdebs05p LFAVMVSLAA L.WRSHGVEP AAVVGHSQGE IAAAHVAGAL TLEDAAKLVA atdebs04p LFSIMVSLAE L.WRAHGVTP AAVVGHSQGE IAAAHVAGAL SLEAAAKVVA

			7/20			
atave02a	QRATLMQTMP	PGTMTTLH	TTPHHITH	HLTAHEN	DLAIAAINTP	
atave05a	QRATLMQTMP	PGTMTTLH	TTPHHITH	HLTAHEN	DLAIAAINTP	
atave04a	QRATLMQTMP	PGTMTTLH	TTPHHITH	HLTAHEN	DLAIAAINTP	
atave08a	QRATLMQTMP	PGTMTTLH	TTPHHITH	HITAHEN	DLAIAAINTP	
atave03a	QRATLMQTMP	PGTMTTLH	TTPHHITH	HLTAHEN	DLAIAAINTP	
atrap02a				GE		
atrap11a				GE		
atrap08a				GE		
atrap12a				GE		
atrap05a				GE		
atrap09a				GE		
atfkb03a				CE		
atfkb07x			•	RP		
atfkb08x				RP		
atnid01a				нтн		
atnid03a				НТН		
atnid02a				нтн		
atnid00a				НТН		
atfkb10a				FTD		
atrap14a				FLSRTGA		
atmon06a				DVDGS		
atmon08a		-		DVDDS		
atmon09a				DVDGS		
atepo02a				AVAPHAA		
atepo03x				AVAPHAA		
atepo08a				AVAPHAA		
atepo00a				AVAPHAA		
atepooda				SVAPHAA		
atnid07a	_			WIAGGR		
				.LAGRED		
attyl07a atsor02a				.LQPYDG		
atsorbla				.LQAAEG		
atnys09a	ARGRLMQALP					
atnys03a atnys12a				.LEGLTD		
atnys12a				.LVD		
-				.LVD		
atnys17a atnys03a				.LTD		
atnys05a				.LTD		
atnysisa atnys07a				.LTD		
•				.LTD		
atnys08a				.LTD		
atnys05a				.LTD		
atnys06a atnys04a				.LTD		
-		AG.GAMIAVE				
atnys14a				.LTD .LGA		
atnys00a atnys10a	ARATLMOALP					
atnys10a		TG.GAMIAIQ		.LDD		
		PG.GAMVALE		.LTD		
atnys13a			•			
atave10a atrif02a	_	SG. GAMVAIE			RVAHAAVNGP	
		AG. GAMVAVQ			.VCVAAVNGP	
atmon03a		AG. GAMLAVQ			RLSLAAVNGP	
atave12a				ALDGREA		
atrif09a				GD		
atmon00a				QLAGHER		
atty103a	*	AG. GAMAALK	ATABETAPL.	.LERRAG		
	-				Arginine	

		14	<del>1</del> /26		. 350	
	301		7			Tood 3M
atave00x	RSTVVSGARE	AVADLVADLT	AAQVRTRMIP	.VDVPAHSPL	MINITERKAA.	Load AT
atdebs00p	RSVLLTGSPE	PVARRVQELS	AEGVRAQVIN	.VSMAAHSAQ	VDDIAEGMR.	LOAG AT
atepo06p	RSTVLAGEPA	ALSEVLAALT	AKGVFWRQV.	KVDVASHSPQ	ADSTREET'I	
atepo07p	RSTVLAGEPA	ALSEVLAALT	AKGVFWRQV.	KVDVASHSPQ	VDPLREEL.1	
atepo01p	RSTVLSGEPA	AIGEVLSSLN	AKGVFCRRV.	KVDVASHSPQ	VDPLREDL.L	
atepo05p	RSTVLAGEPA	ALAEVLAILA	AKGVFCRRV.	KVDVASHSPQ	IDPLRDEL.L	
atsoralx	DSTVLAGEPD	ALDALLQALE	RKNVFCRRV.	AMDVAPHCPQ	VDCLRDEL.F	Benzoate-CoA
atfkb01p	ESTVVAGDPA	AVERVLARYE	AEGVRVRRI.	AVDYASHTPH	VEAIEAQL.A	
atfkb09p	ESTVVAGDPS	AVERVLARYE	AEGVRVRRI.	AVDYASHTPH	VEAIQEQL.A	
atrap03p	ASTVIAGTPE	AVDHVLTAHE	ARGVRVRRI.	TVDYASHTPH	VELIRDEL.L	
atrap06p	ASTVIAGTPE	AVDHVLTAHE	ARGVRVRRI.	TVDYASHTPH	VELIRDEL.L	
atrap04p	ASTVIAGTPE	AVDHVLTAHE	ARGVRVRRI.	TVDYASHTPH	VELIRDEL.L	
atrap13p	ASTVIAGTPE	AVDHVLTAHE	AQGVRVRRI.	TVDYASHTPH	VELIRDEL.L	
atrap01p	ASTVVAGAPE	AVDRVLAVHE	ARGVRVRRI.	AVDYASHTPH	VELIRDEL.L	
atrap07p	ASTVVAGAPE	AVDRVLAVHE	ARGVRVRRI.	AVDYASHTPH	VELIRDEL.L	
atrap10p	ASTVIAGTPE	AVDHVLTALR	QRGAGAAD	HVDYASHTPH	VELIRDEL.L	
atfkb04x	ATTIVSGRPD	AVETLIADYE	ARGVWVTRL.	VVDCPTHTPF	VDPLYDEL.Q	C5 unit
attyl04p	ASTVVSGDRR	AVAGYVAVCO	AEGVOARLIP	.VDYASHSRH	VEDLKGELE.	
atty104p	ASTVVSGDRR	AVAGYVAVCO	AEGVOARLIP	.VDYASHSRH	VEDLKGELE.	
attyl01p	ASTVVSGDRR	AVAGYVAVCO	AEGVOARLIP	. VDYASHSRH	VEDLKGELE.	
atty102p	ASTVVSGDRR	AVAGYVAVCO	AEGVOARLIP	.VDYASHSRH	VEDLKGELE.	
• -	ASTVVSGDRR	AVACYVAVICO	AEGVOARLTP	.VDYASHSRH	VEDLKGELE.	
attyl00p	W21 A A 2 G D VIV	ATART.VALLT	GEGVHARPIP	GVDTAGHSPO	VDALRAHL.L	Etmalonyl-CoA
atnid05b	COLAVAGUE	ALBELTABLE	PECIBARALA	GVDTAGHSAO	VDGLKEHL.F	Etmalonyl-CoA
atty105b	DOMESTICA	AT PERCAPI C	AECUT.DWDT.D	GVDFAGHSPO	VEEFRAEL.L	MeOmalonyl CoA
atnid06x		MIREFORMS	TECTDARDI.	AUDVASHSSH	VETTRDALHA	
atdebs01p		ELUKLVASCI	ARGLRARVID	VCVASHCPO	TDOTHDLL T	
atmon02p		HVAAVVADAE	ARGLRARVID	VCYASHCPO	TDOTHDLL.T	
atmon10p	SSTVISGPPE	HVAAVVADAE	ARGLRARVID	VCVASHCPO	TOOLHOLL T	
atmon04p		HVAAVVAEAE	ERGLRARVID	VGYASHGPO	TDOTHDLL T	
atmon07p		HVAAVVADAE	AQGLRARVID	OGDHSEVOV.	TDOLHDLL.T	
atmon11p		HVAAVVADAE	ARGLRARVID	VCANCHCDU &	TDOTHDIA. T	
atmon12p	SSTVISGPPE	HVAAVVADAE	WEGTEWEATD	SDANGHCEO.	T.DATT.DOL. T	Et/mal-CoA
atmon05b	SSTVISGPPE	GIAAVVADAQ	ARELRGRVID	OGSHSEVOU	VDATTDEL T	
atmon01p	SSTVISGPPE	QVAAVVADAE	GVGIRARAIP	Tundanna V	VEPURDEL V	,
atdebs02p		AAREFLEICE	DEGVRAKTLP	TADINGMINO.	VEETRETT. L	•
atdebs06p	SSVVVSGDPE	ALAELVARCE	DEGARANTE	TOOLS TOOLS	VODIBEEL I	
atave01p	RSTAVSGDAE	AVDEVLAYCA	GTGVRARRIP	ADJUSTICE	VOPT.REEL, I	
atave07p		AVDEVLAYCA	GTGVRARRIP	. VDIABICE:	VOLUMBE.	
atave06p		AVDEVLARCT	DTGLRAKRIP	VDIABILOFI	VOLUMBE.	
atave09p		AVEELLINCA	DTGLRAKRIP ADDIRARRIA	. ADIVOUCE:	VEDIHEEL I	
atnys01p	RSVVVAGEPE	ALDALHARLT	ADDINARRIA	ADIVIDIDA ADIVIDIDA	VEDIMEEL T	
atnysllp	RSVVVAGEPE	ALDALHARLT	ADDIRARRIA	TOURSHOUS.	VEDINDED.I	
atrif05p	ASVVIAGDAE	ALTEAVEVLG	GRRVA	INTROVIOR.	VEDIQUID.A	<b>.</b>
atrif07p		ALDEALEVLA	GDGVRVRQVA	MIDGALUV.	VEDIKUID.	<b>.</b>
atrif08p	SSVVIAGDAE	ALDQALEALT	GQDIRVRRVA	INTROALUV.	TODIQUEST.	<b>.</b>
atrif10p	ASVVIAGDAQ	ALDETLEALS	GAGIRARRVA	MINGALU.	1 AEDIEDID. 1 AEDIEDID.	<u>,</u>
atrif03p	SSVVIAGDAQ	ALDEALEALA	GDGVRVRRVA	MINGAIUV.	. AEVIEDIT. 1	<b>.</b>
atrif06p	ASVVIAGEAQ	ALDEVVDALS	GOEVRVRRVA	VDIGSTING	i inganduki 1 1 Aberennes	<b>.</b>
atrif04p	•	ALDEALDALD	DOGVRIRRVA	.VDYASHTRI	· venarumu.	3 \
atrif01p	SSVVIAGDAH	ALDATLEILS	GEGIRVRRVA	.VDYASHTRI	ARDIKUTU.	<del>1</del>
atnys02p	SSVVVSGDTD	ALDALHTACO	EQGVRARKVS	. VDYASHGR	I VEAVKUEL.	73. T
atfkb02p	ASIVVAGAAD	AVEELLAATI	HARRIA	. VDYASHTAI	1 VESIKGAL.	ш <b>г</b>
atave11p	RSAVVSGEPE	AVDALVEELS	HEDVPARRLM	.VDWASHSP(	NEWIGHT!	ր •
atdebs03p		ALRAFSEDCA	A AEGIRVRDII	.VDYASHSP	TEKAKREP	L)
atnid04p	ETTVVCGAPO	AVDSLLGVL(	Q GEGVRVRRII	.VDYASHSR	A VEGIRDEL.	H.
atdebs05p		PLDELIAECE	E AEGITARRII	.VDYASHSP	O AMBIEDO.	у П
atdebs04p	GTSVVAGPT	A ELDEFFAEAI	E AREMKPRRIA	A .VKYASHSP.	C AWKIEDKY.	<b>.</b>

```
atave02a TSLVISGTPH TVOHITTLCO QQGIKTKTL. PTNHAFHSPH TNPILNQLH.
atave05a TSLVISGTPH TVQHITTLCQ QQGIKTKTL. PTNHAFHSPH TNPILNQLH.
atave04a TSLVISGTPH TVQHITTLCQ QQGIKTKTL. PTKNAFHSPH TNPILNQLH.
atave08a TSLVISGTPH TVQHITTLCQ QQGIKTKTL. PTNHAFHSPH TNPILNQLH.
atave03a TSLVISGTPH TVQHITTLCQ QQGIKTKTL. PTNHAFHSPH TNPILNQLH.
atrap02a SSVVLSGDEA AVLQAAEGLG ....KWTRL. PTSHAFHSAR MEPMLEEFR.
atrap11a
         SSVVLSGDEA AVLQAAEGLG ....KWTRL. ATSHAFHSAR MEPMLEEFR.
atrap08a
         SSVVLSGDEA AVLQAAEGLG ....KWTRL. ATSHAFHSAR MEPMLEEFR.
atrap12a
         SSVVLSGDEA AVLQAAEGLG ....KWTRL. ATSHAFHSAR MEPMLEEFR.
         SSVVLSGDET AVLQAAAALG ....KSTRL. ATSHAFHSAR MEPMLEEFR.
atrap05a
         SSVVLSGDEA AVLQAAEGLG ....KWTRL. ATSHAFHSAR MEPMLEEFR.
atrap09a
         ASIVLSGDED AVLDVAARLG ....RFTRL. RTSHAFHSAR MEPMLDEFR.
atfkb03a
atfkb07x HSVVLSGDEG PVLDVAQQLG ....IHHRL. PTRHAGHSAR MDPLVAPLL. MeOmalonyl-CoA
atfkb08x HSVVLSGDED AVLDVAQRLG ....IHHRL. PAPHAGHSAH MEPVAAELL. MeOmalonyl-CoA
atnid01a
         THCVLSGPRT ALEETAQQLH QQGIRHTWL. KVSHAFHSAL MDPMLGAFR.
         THCVLSGPRT ALEETAQHLR EQNVRHTWL. KVSHAFHSAL MDPMLGAFR.
atnid03a
         THCVLSGPRT ALEETAQHLR EQNVRHTWL. KVSHAFHSAL MDPMLGAFR.
atnid02a
         THCVLSGPRT ALEETAQHLR EQNVRHTWL. KVSHAFHSAL MDPMLGAFR.
atnid00a
atfkb10a
         SAVVLTGAPD DVAAFEREWA AAGRRAKRL. DVGHAFHSRH VDGALDDFR.
         EAVVVSGEPE PVADFEAAWT ASGREARKL. KVRHAFHSRH VEAVLDEFR.
atrap14a
atmon06a DSTVISGPSD EVDRIAGVWR ERGRKTKAL. SVSHAFHSAL MEPMLAEFT.
atmon08a DSTVISGPSG EVDRIAGVWR ERGRKTKAL. SVSHAFHSAL MEPMLAEFT.
atmon09a DSTVISGPSG EVDRIAGVWR ERGRKTKAL. SVSHAFHSAL MEPMLGEFT.
atepo02a EQVVIAGVEQ AVQAIAAGFA ARGARTKRL. HVSHAFHSPL MEPMLEEFG.
atepo03x EQVVIAGVEQ AVQAIAAGFA ARGARTKRL. HVSHASHSPL MEPMLEEFG. Mal/mmal
atepo08a EQVVIAGAEK FVQQIAAAFA ARGARTKPL. HVSHAFHSPL MDPMLEAFR.
atepo00a DQVVIAGAGQ PVHAIAAAMA ARGARTKAL. HVSHAFHSPL MAPMLEAFG.
atepo04a DAVVIAGAEV QVLALGATFA ARGIRTKRL. AVSHAFHSPL MDPMLEDFQ.
atnid07a
          DSLVLSGDEQ AVVSAAGELA ARGRRTKRL. SVSHAFHSPH MDAMLADFR.
         RSVVISGAEE AVAEAAAQLA GRGRRTRRL. RVAHAFHSPL MDGMLAGFR.
attyl07a
         LSTVVAGDED AVVEIARQAE ALGRKTTRL. RVSHAFHSPH MDGMLDDFR.
atsor02a
atsorbla LSTVVAGDED AVLKIARQVE ALGRKATRL. RVSHAFHSPH MDGMLDDFR.
atnys09a SAVVLSGAEA TVTALAEOLA ADGRKTRRL. RVSHAFHSPL MEPMLDAFR.
atnys12a RSVVVAGVEE DVLLLADLFA ADGRRTKRL. RVSHAFHSPL MDAMLDDFA.
         VSVVVSGVEA AVGQVVDQLV ERGRRVRRL. AVSHAFHSPL MDPMLDAFR.
atnys16a
         VSVVVSGVEA AVGQVVDQLV ERGRRVRRL. AVSHAFHSPL MDPMLDAFR.
atnys17a
          TSVVVAGTEE AVAAIGARFT AQDRKTTRL. RVSHAFHSPL MDPMLAEFR.
atnys03a
atnys15a
          TSLVVSGDET ATLAVAARLA EQGRRTTRL. RVSHAFHSPL MDPMLAEFR.
          NALVVSGVED AAVEIGARFA AEGRRTTRL. HVSHAFHSPL MDPMLAEFR.
atnys07a
          TSVVISGAEE ATQTVAQHFA DQGRRTTAL. RVSHAFHSPL MDPMLAEFR.
atnys08a
          TSVVVSGAES AARTVADRLA ENGRKTTRL. RVSHAFHSPL MDPMLAEFR.
atnys05a
atnys06a
          TSVVISGAEE ATQTVAQHFA DQGRRTTAL. RVSHAFHSPL M..MLAEFR.
atnys04a
          TSVVVSGYEN ATLAVARHFA DQGRRTTRL. RVSHAFHSPL MAPMLDDFR.
          TAVVLSGAGD AVTALGQALA ERGHRTTRL. RVSHAFHSHL MDPMLADFR.
atnvs14a
atnys00a TAVVVAGAED AVROLTARFA DRGRRTSRL. AVSHAFHSPL MEPMLDAFR.
atnys10a QSVVISGDEE AAETIAATFA ERGRKTKRL. RVSHAFHSPR MDGMLDAFR.
atnys18a RSVVVAGAED AALAVRRHFD DLGRRTTRL. PVSHAFHSPL MDPMLDAFR.
atnys13a RSVVVAGAED AVRAVADRLA ADGRRTRRL. TVSHAFHSPL MDPMLTDFA.
atave10a
         RSIVLSGDED AVLDLAQQWA ARGRRTRRL. RTSHAFHSPH MDAMLGDFR.
          DSVVLSGTEA AVLAVADELA GRGRKTRRL. AVSHAFHSPL MEPMLDDFR.
atrif02a
          TAVVVSGEAA AVGEVEKALR GRGLKTKRL. NVSHAFHSPL IEPMLDDFR.
atmon03a
atave12a ASVVFSGAED EVGNMADWFA ERGRRVKRL. RTGHAFHSPL MDPMLEEFQ.
atrif09a SAVVLSGDAD AVVAAAARMR ERGHKTKQL. KVSHAFHSAR MAPMLAEFA.
atmon00a DSVVVSGDRA TVDELTAAWR GRGRKAHHL. KVSHAFHSPH MDPILDELR.
atty103a SSVVVSGDEA AVLELLEQWR AEGREARRL. AVSHAFHSPR MDGMLTQFD.
                                              ****
                                                    HAFH/YASH/TAGH motif
```

	351	. •	0,20		400
atave00x		SRIPFHSSVT	C CDT	DEEDET DAAV	400 WYRNMSSTVR
					•
atdebs00p		SEVPFYASLT			WRRSFRLPVR
atepo06p		AAVPMRSTVT			WADNLRQPVR
atepo07p		AAVPMRSTVT			WADNLRQPVR
atepo01p		AAVPMRSTVT			WMNNLRQPVR
atepo05p	_	ATVSMRSTVT			WADNVRQPVR
atsoralx		AQIPIVSEVT			WVRNFGDPAL
atfkb01p		PSVPWWSTVD			WYRNLRQPVA
atfkb09p		PSVPWWSTVD			WYRNLRQPVA
atrap03p		PLVPWLSTVD			WYRNLREPVG
atrap06p	-	PVVPWLSTVD			WYRNLREPVG
atrap04p		PVVPWLSTVD			WYRNLREPVG
atrap13p	_	PLVPWLSTVD			WYRNLREPVG
atrap01p		PVVPWLSTVD			WYRNLREPVG
atrap07p		PVVPWLSTVD			WYRNLREPVG
atrap10p		PLVPWLSTVD		-	WYRNLREPVG
atfkb04x		PEIPWFSTAD			WFRNMRNPVG
atty104p		PRVPVCSTVA			WFRNLRNRVE
atty106p		PRVPVCSTVA	_		WFRNLRNRVE
attyl01p		PRVPVCSTVA			
atty102p		PRVPVCSTVA			WFRNLRNRVE
atty100p		PRVPVCSTVA			WFRNLRNRVE
atnid05b		ADIPFYSTVT			WYRNMREPVE
attyl05b		SDIPFYSTVT			WYRNMREPVE
atnid06x		SRIPFFSTVT			WYRNTREPVE
atdebs01p		GFVPFFSTVT			WYRNLRRTVR
atmon02p		TDVAFYSTVT			WVTNLRQPVR
atmon10p		TDVAFYSTVT		•	WVTNLRQPVR
atmon04p		TDVAFYSTVT			WVTNLRQPVR
atmon07p		TDVAFYSTVT			WVTNLRQPVR
atmon11p	<del></del>	TDVAFYSTVT			WVTNLRQPVR
atmon12p		TDVAFYSTVT			WVTNLRQPVR
atmon05b		TDVAFYSTVT			WVRNVRRTVR
atmon01p		APVAFYSAVT			WVTNLRRPVR
atdebs02p	_	AEVPFFSTLT			WYRNLRHPVE
atdebs06p		AAIPLYSTLH			***
atave01p	_	SGVPFFSTVE			WYRNLHQPVR
atave07p		SGVPFFSTVE			
atave06p	-	STVPFFSTVE			
atave09p	<del>-</del>	STMPFFSTVV			_
atnys01p		SEVPFFSTVT			WFRNLRGRVR
atnys11p		SEVPFFSTVT			WFRNLRGRVR
atrif05p		PVVPFYSTVA			WYRNLRNQVG
atrif07p		PDVPFRSTVT			WYRNLRNQVR
atrif08p		PTLPFFSTLT			WYRNLRNQVG
atrif10p		PLVPFLSTLT			WYRNLRGRVR
atrif03p		PAIPFYSTVL			WYRNLRQQVR
atrif06p		PKVPFYSTLI			WYRNLRNQVG
atrif04p		PEVPFYSTVT			WYRNLRRQVR
atrif01p		PAVPFYSTVT			WYRNLRNQVR
atnys02p		PEVPFYSTVT			WYTNLRQTVR
atfkb02p		PEIPFFSTVD			WYDNVRCPVR
atave11p		GDVPFYSTVT			WYRNLRQVVR
atdebs03p		ARVTFHSTVE			WYRNLRETVR
atnid04p		GRVPFYSTVE			WYRNLRQRVR
atdebs05p		ADVALYSTTT			WYANLREQVR
atdebs04p	AELGTITAVR	GSVPLHSTVT	GEVI.	.DTSAMDASY	WYRNLRRPVL
•		Fig	20		
		Fig	~~		
		•			

		_	/	•	
		1	7/26		
atave02a	OHTOTLTYHP	PHTPLITANT		PPDOTTPHY	WTQQARNTVD
atave05a		PHTPLITANT			WTQQARNTVD
atave04a		PHTPLITANT			WTQQARNTVD
atave08a	QHTQTLTYHP	PHTPLITANT			WTQQARNTVD
atave03a		PHTPLITANT			WTQQARNTVD
atrap02a	AVAEGLTYRT	PQVA			WVRQVRDTVR
atrap11a	AVAEGLTYRT	PQVS			WVRQVRDTVR
atrap08a	AVAEGLTYRT		MA	AGDQLTTTEY	WVRQVRDTVR
atrap12a	AVAEGLTYRT	PQVS		VGDQVTTAEY	
atrap05a	TVAERLTYQT				WVRQVRDTVR
atrap09a	AVAQGLTYHA	PGVV		AGDRVMTAEY	
atfkb03a		PKLP		AGADCATPEY	
atfkb07x		PHT		IPEDPTTAAY	
atfkb08x		PHT		IPNDPTTAEY	
atnid01a		PTIPLISNLT			WIDHARHTVR
atnid03a		PTIPLISNLT			WIDHARHTVR
atnid02a atnid00a		PTIPLISNLT	GQIADPNHL.		WIDHARHTVR
atfkb10a		PTIPLISNLT	GQIADPNHL.		WIDHARHTVR
atrap14a	TALESLKFRA	ARLPVVSTTT		TPEH	WLROVRRPVR
atmon06a	EAIRGVKFRO		GRLIDQDEMG GERA		WARHVRNAVL
atmon08a	EAIREVKFTR		GLEA		WARHVROTVL
atmon09a	EAIRGVKFRO		GERA		WARHVROTVL
atepo02a	RVAASVTYRR		GKVVT.DEL.		WVRHVREAVR
atepo03x	RVAASVTYRR		GKVVA.DEL.		WVRHVREAVR
atepo08a	RVTESVTYRR		GKPCT.DEV.		WVRHAREAVR
atepo00a	RVAESVSYRR		GKACT.DEV.		WVRHAREVVR
atepo04a	RVAATIAYRA		GHVAG.PEI.		WVRHVRSAVR
atnid07a	AVAESVTYRT	PRLPIVSEVT	GRPAAPSEL.		WTROIREPVR
atty107a	EVAAGLRYRE	PELTVVSTVT	GRPARPGEL.	TGPDY	WVAQVREPVR
atsor02a	RVAQSLTYHP	ARIPIISNVT	GARATDHEL.	ASPDY	WVRHVRHTVR
atsorb1a	RVAQGLTFHP	ARIPIISNVT	GARATDQEL.	ASPET	WVRHVRDTVR
atnys09a	AVVEDLTLQP		GKPATVAQL.	TSADY	WVDHVRHAVR
atnys12a	AVARGLTYHP		GGLATAEQV.		WVGHVRAAVR
atnys16a	AVAEGLEYHQ		GEVAAAEEL.		WVRHVRATVR
atnys17a		PRIPVVSNVT	GEVAAAEEL.		WVRHVRATVR
atnys03a		PRIPVLSNLT			WVRHVREAVR
atnys15a	AVAEGLSYGE VVAEGLSYAA	PQIPVVSNLT			WVRHVREAVR
atnys07a atnys08a		PSLPVVSNLT	GQVATADEL.		WVRHVREAVR WVRHVREAVR
atnys05a		PTLPVVSNLT		CSAEY	
atnys06a		PTLPVVSNLT			
atnys04a	AVVESTOFTA	PTTPVVSNLT	GETAPARAT.		WVRHVREAVR
atnys14a		PRIPVVSNLT			WVRHVRGTVR
atnys00a		PSIPLVSNLT			WVRHVRDTVR
atnys10a		PRIPLVSDLT			WVRHVREAVR
atnys18a		PEIPVVSNLT			WVCHVRQAVR
atnys13a		PRIPLVSTLL			WVRHVRETVR
atave10a		PRIPVVSNVT			WVEHARSTVR
atrif02a		GSLPVVSTLT			WVGQVRNAVR
atmon03a		PTLPVVSNLT			WVRHVRRPVR
atave12a	QVAASLTYSE	PAIPMVSTLT	GDIVAAGEL.		WVRQVRRTVR
atrif09a		PEIPVVSNVT		TEPGY	WAEHVRRPVR
atmon00a		PVIPVVSNVT			
atty103a	RVARTLTFAP	PTIPLVSTLT	GTPVTEETL.	CTADH	WVRQAREPVR

	401	, ,	720		450
	401				450
atave00x	FEPAARLLLQ				DTTG
atdebs00p	FDEAIRSALE				DAEG
atepo06p	FAAAAQALLE			-	AE
atepo07p				DEIQTA	
atepo01p	FAEVVQAQLQ	GGH.GLFVEM	SPHPILTTSV	EEMRRA	
atepo05p				EEIRRA	
atsora1x	FSTAIDHLLQ	EGF.DIFLEL	TPHPLALPAI	ESNLRR	SG
atfkb01p	MDTAVSELDG	SLFIEC	SAHPVLLPAL	DQ	
atfkb09p	MDTAIGELDG	SLFIEC	SAHPVLLPAL	DQ	
atrap03p	FHPAVGQLQA	QGD.TVFVEV	SASPVLLQAM	DD	
atrap06p	FHPAVGQLQA	EGD. TVFVEV	SASPVŁLQAM	DD	
atrap04p	FHPAVSQLQA	QGD.AVFVEV	SASPVLLQAM	DD	
atrap13p	FHPAVSQLQA	QGD.TVFVEV	SASPVLLQAM	DD	
atrap01p				DD	
atrap07p				DD	
atrap10p	FHPAVSQLQA	QGD.TVFVEV	SASPVLMQAM	DD,	
atfkb04x				NG	
atty104p	<b>FSAVVGGLLE</b>	EGH.RRFIEV	SAHPVLVHAI	EQTA	EAAD
atty106p	FSAVVGGLLE	EGH.RRFIEV	SAHPVLVHAI	EQTA	EAAD
atty101p	<b>FSAVVGGLLE</b>	EGH.RRFIEV	SAHPVLVHAI	EQTA	EAAD
attyl02p	FSAVVGGLLE	QGH.RRFIEV	SAHPVLVHAI	EQTA	EAAD
attyl00p	FSAVVGGLLE	EGH.RRFIEV	SAHPVLVHAI	EQTA	EAAD
atnid05b	FERATRALIA	DGH.DVFLET	SPHPMLAVAL	EQTV	TDAG
attyl05b	FEKAVRALIA	DGY.DLFLEC	NPHPMLAMSL	DETL	TDSG
atnid06x				DEIA	ADEG
atdebs01p				EEIG	
atmon02p				EETIEQ	
atmon10p				EETIEQ	
atmon04p				EETIEQ	
atmon07p				EETIEQ	
atmon11p				QETIEQQA	
atmon12p				EETIER	
atmon05b				EGLIER	
atmon01p				QETFEE	
atdebs02p				QETL	
atdebs06p	FDEAVSAOSP	DGH.ATFVEM	SPHPVLTAAV	QE	IA
atave01p	FSDAVOALAD	DGH.RVFVEV	SPHPTLVPAI	EDTTEDTA	ED
atave07p				EDTTEDTA	
atave06p	FSHAIOTLTD	DGH.RAFIEI	SPHPTLVPAI	EDTTENTT	EN
atave09p	FSHAIOTLTD	DGH.RPFIEI	SPHPTLVPAI	EDTTENTT	EN
atnys01p				LDLI	
atnys11p	FADAVADLLA	AEY.RAFVEV	SSHPVLSMAV	QEAI	DEAG
atrif05p	FGPAVAELIE	OGH. GVFVEV	SAHPVLVOPI	SELT	D
atrif07p	FGPAVAELLE	OGH. GVFVEV	SAHPVLVOPI	SELT	D
atrif08p				SAIA	
atrif10p				TELT	
atrif03p	FGPSVADLAG	LGH. TVFVEI	SAHPVLVOPL	SEIS	DD
atrif06p	FGPAVAELVR	OGH GVFVEV	SAHPVLVOPL	SELS	DD
atrif04p	FGPAVAELIE	OGH. RVFVEV	SAHPVLVOPI	NELV	DD
atrif01p	FGAAATALLE	OGH TVFVEV	SAHPVTVOPL	SELT	GD
atnys02p	MEEATRALLA	AGH.RVFIEV	SPHPVLAAPI	QETQEAVA	EATG
atfkb02p	FGAAAARTAE	LGH RVFVEA	SPHPVT.TTAT.	ADTLAG	н
atave11p	FRDATOATA	AGH TUFTEA	CPHPAVAVGV	OETLDE M	GD
atdebs03p	FADAVTRT.AF	SGY DARTEN	SPHPVANION	EEAVEE A	DGAE
atnid04p	FRSATRAMTA	DGV DARVEC	SPHPVT.TVDV	ROTLED A	GA.
atdebs05p	FODATROLAR	AGE DARVEV	SPHPVT.TVCT	EATLDS A	LPAD
atdebs05p	PEODVECTAR	OCE DAEAEA	SPHPVT.T.MAV	EETA	EHAG
acaenanah	7 DA114 HOTA D				
		Fig	29		
		J			

		19	1/26		
atave02a	YATTTQTLHQ			HHNLPNPPTT	TLTLTHPHHH
atave05a	YATTTQTLHQ				TLTLTHPHHH
atave04a	YATTTQTLHQ				TLTLTHPHHH
atave08a			GPDNTLTTLT		TLTLTHPHHH
atave03a	YATTTQTLHQ				TLTLTHPHHH
atrap02a	FGEQVASFED				
atraplla				DG	
atrap08a				DG	
atrap12a				DG	
atrap05a				DG	
atrap09a				DG	
atfkb03a				DG	
atfkb07x	FQAHAERYPG	ATFLEI	GPNQDLSPVV	DG	
atfkb08x	FHAHTQRYPD	AVEVEI	GPGQDLSPLV	DG	
atnid01a	FADAVQTAHD	QR.TTTYLEI	GAHPTLTTLL	HHTLDNP	
atnid03a	FADAVQTAHH	QG.TTTYLEI	GPHPTLTTLL	HHTLDNP	
atnid02a	FADAVQTAHD	QR.TTTYLEI	${\tt GPHPTLTTLL}$	HHTLDNP	
atnid00a	FADAVQTAHH	QG.TTTYLEI	GPHPTLTTLL	HHTLDNP	
atfkb10a				SENTGGSAGT	
atrap14a				VECLGGDA.S	FH
atmon06a	FQPAIAQVAD				.SQES
atmon08a				QHTLDDVTDR	
atmon09a				QHTLDHITEP	EGPEP
atepo02a	FADGVKALHE				
atepo03x				PACLPEAEP.	
atepo08a			GPKPTLLGLV		
atepo00a				PACMPDARP.	
atepo04a				PACLGEADA.	
atnid07a				RECAAG	
atty107a				EECLED	
atsor02a				QDALGQ	
atsorb1a				QDALGH	
atnys09a				QDCLDA	
atnys12a				RESLTD	
atnys16a		-		RGVL	
atnys17a				AACL.F	
atnys03a				QESL	
atnys15a				QQSA	
atnys07a					
atnys08a				QQSL	
atnys05a atnys06a				RETV	
atnys04a				QESA	
atnys04a atnys14a				RQCA	
atnys00a				RDTL.G	
atnys00a				EDTL.G	
atnysida atnys18a				RENL	
atnys10a atnys13a				QQTLDT	
atave10a				QDSLSA	
atrif02a				LGTLGG	
atmon03a				QDGLPA	
atave12a				EECLEATADS	
atrif09a				EET	
atmon00a				RDCFPAPADR	
atty103a				RDCADDRPDG	

	451		0/26		
atave00x		DDCCcmr nine	7.07.3.03		500
atdebs00p	TUDIATEDIT	* KKGQGTLDHF	LISTAOTECH	GETSATTV	LSARLTALSP
atepo06p	OCCANA COL	DRGQGGMRRE	LLAAAQAFTG	GVAVDWTA	AYDDVGA.EP
atepo00p	OCCANA COL	RRGQUERATL	LEALGTLWAS	GYPVSWAR	LFPAGG
atepo07p	DACANY COL	RRGQDERATL	LEALGTLWAS	GYPVSWAR	LFPAGG
atepoolp	PECTATA COL	RRGQDERPAM	LEALGTLWAQ	GYPVPWGR	LFPAGG
atsora1x	DECLAR DOL	RRGQUERLSM	LEALGALWVH	GQAVGWER	LFSAGGAGL.
atfkb01p	KKGAAT'52T	RRNEDERGVM	LDTLGVLYVR	GAPVRWDN	VYPAAF.
atfkb01p	E DEW ACT	RTDDGGWDRF	LAALAQAWTQ	GADVDWTT	LIEPA
-	PERTA PER	RTDDGGWDRF	LTALAQAWTQ	GADVDWTT	LIAPA
atrap03p	DIVITY ATL	RRDDGDATRM	LTALAQAYVH	GVTVDWPA	ILG.T
atrap06p	DVVIV.ATL	RRDDGDATRM	LTALAQAYVH	GVTVDWPA	ILG.T
atrap04p	DVVIV.ATL	RRDDGDATRM	LTALAQAYVH	GVTVDWPA	ILG.T
atrap13p	DVVIV.ATL	RRDDGDATRM	LTALAQAYVH	GVTVDWPA	ILG.T
atrap01p	.DVVTV.ATL	RRDDGDATRM	LTALAQAYVE	GVTVDWPA	VLG.T
atrap07p	.DVVTV.ATL	RRDDGDATRM	LTALAQAFVE	GVTVDWPA	ILG.T
atrap10p	.DVVTV.ATL	RRDDGDATRM	LTALAQAYVH	GVTVDWRA	VLGDV
atfkb04x	TTV.GTL	RR.GGGADRV	LDSLAKAHTV	GVAVDWST	VVAATGAADD
attyl04p	RSVHAT.GTL	RRQDDSPHRL	LTSTAEAWAH	GATLTW	• • • • • • • • • • • • • • • • • • • •
attyl06p	RSVHAT.GTL	RRQDDSPHRL	LTSTAEAWAH	GATLTW	• • • • • • • • • • • • • • • • • • • •
attyl01p	RSVHAT.GTL	RRQDDSPHRL	LTSTAEAWAH	GATLTW	• • • • • • • • • • • • • • • • • • • •
atty102p	RSVHAT.GTL	RRQDDSPHRL	LTSTAEAWAH	GATLTW	• • • • • • • • • • •
atty100p	RSVHAT.GTL	RRQDDSPHRL	LTSTAEAWAH	GATLTW	• • • • • • • • • •
atnid05b	TDAAVL.GTL	RRRHGGPRAL	ALAVCRAFAH	GVEVDPEA	VF
atty105b	GHGTVM.HTL	RRQKGSAKDF	GMALCLAYVN	GLEIDGEA	LF
atnid06x	VAATAL.HTL	QRGAGGLDRV	RNAVGAAFAH	GVRVDWNA	LF
atdebs01p	ADLSAI.HSL	RRGDGSLADF	GEALSRAFAA	GVAVDWES	VH
atmon02p	MPATVV.PTL	RRDHGDTTQL	TRAAAHAFTA	GADVDWRR	WF
atmon10p	IPATVV.PTL	RRDHGDTTQL	TRAAAHAFTA	GAPVDWRR	WF
atmon04p	IPATVV.PTL	RRDHGDTTQL	TRAAAHAFTA	GADVDWRR	WF
atmon07p	IPATVV.PTL	RRDHGDTTQL	TRAAAHAFTA	GATVDWRR	WF
atmon11p	GTAVTI.PTL	RRDHGDTTQL	TRAAAHAFTA	GAPVDWRR	WF
atmon12p	MPATVV.PTL	RRDHGDAAQL	TRAAAQAFGA	GAEVDWTG	WF
atmon05b	VPATVV.PTL	RRDHGDTTQL	ARAAAHAFAA	GADVDWRR	WF
atmon01p	VDAVTV.PTL	RREDGGRARL	ARSLAQAFGA	GCAVRWEN	WF
atdebs02p	SDAAVL.GTL	ERDAGDADRF	LTALADAHTR	GVAVDWEA	VL
atdebs06p	ADAVAI.GSL	HRDTAE.EHL	IAELARAHVH	GVAVDWRN	VF
atave01p	VTAI.GSL	RRGDNDTRRF	LTALAHTHTT	GIGTPTTWHH	HY
atave07p	VTAI.GSL	RRGDNDTRRF	LTALAHTHTT	GIGTPTTWHH	HY
atave06p	ITAT.GSL	RRGDNDTHRF	LTALAHTHTT	GIGTPTTWHH	HY
atave09p	ITAT.GSL	RRGDNDTHRF	LTALAHTHTT	GIRTPTTWHH	HY
atnys01p	VTAVAT.GTL	RRDQGGAGRF	LLSAAEVFVR	GVDVDWAG	AF
atnys11p	VPAVAA.GTL	RRDQGGTDRF	LLSAAEVFVR	GVDVDWAG	LF
atrif05p	AVVT.GTL	RRDDGGVRRL	LTSMAELFVR	GVPVDWAT	MA
atrif07p	AVVT.GTL	RRDDGGLRRL	LTSMAELFVR	GV RVDWAT	LV
atrif08p	TDAVVT.GSL	RREEGGLRRL	LTSMAELFVR	GVDVDWAT	MV
atrif10p	TAAVVT.GSL	RRDDGGLRRL	LTSMAELFVR	GVEVDWTS	LV
atrif03p	AVVT.GSL	RRDDGGLRRL	LASAAELYVR	GVAVDWTA	AV
atrif06p	AVVT.GSL	RREDGGLRRL	LTSMAELYVQ	GVPLDWTA	VL
atrif04p	TEAVVT.GTL	RREDGGLRRL	LASAAELFVR	GVTVDWSG	VL
atrif01p	AI.GTL	RREDGGLRRL	LASMGELFVR	GIDVDWTA	MV
atnys02p	GSAVVL.GSL	RRDEGGPRRF	LTSLAEAHTH	GAPVDWTT	TF
atfkb02p	PNTAVT.GTL	RRGDGGARRF	TRSLAELWVR	GVPVSW	
atave11p	LDSLVV.GSL	RRGEGGLRRF	LMSVAELFVG	GVAVEWSG	VF
atdebs03p	.DAVVV.GSL	HRDGGDLSAF	LRSMATAHVS	GVDIRWDV	AL
atnid04p	.GAVAV.GSL	RRDDGGLRRF	LTSAAEAQVA	GVPVDWAA	LC
atdebs05p	AGACVV.GTL	RRDRGGLADF	HTALGEAYAQ	GVEVDWSP	AF
atdebs04p	AEVTCV.PTL	RREQSGPHEF	LRNLLRAHVH	GVGADL	
		E:- 0		<b>-</b>	

atave02a PQTH......21/26. atave05a PQTH..... LLTNL AK....TT T..TWHPHHY atave04a PQTH..... TT T..TWHPHHY atave08a PQTH..... TT. T..TWHPHHY atave03a PQTH..... TT T..TWHPHHY atrap02a .....IAML HGD.HE.... ..AQAAVGAL AHLYVNG.VS V..EW.SAVL atrap11a .....VAML HGD.HE.....AQAAVGAL AHLYVNG.VS V..EW.SAVL atrap08a .....VAML HGD.HE.....AQAAVSAL AHLYVNG.VT V..DW.PALL atrap12a .....VAML HGD.HE.... ..IQAAIGAL AHLYVNG.VT V..DW.PALL atrap05a .....VAML HTD.HE.... .AQAAISAL AHLYVNG.VT V..DW.TALL atrap09a .....VAML HGD.HE.... .TQAAIGAL AHLYVNG.VT V..DW.TALL atfkb03a .....IPVL HGE.DE.... ..ARSAMTAL ARLHTGG.VA V..DW.PEVI atfkb07x .....IPTQ TGTPEE......VQALHTAL ARLHTRG.GV V..DW.PTVL atfkb08x .....IALQ NGTADE.... ..VHALHTAL ARLFTRG.AT L..DW.SRIL atnid01a ....TTIPTL HREHPEPETL TTAL....AT ..LHTTGHTT T....... atnid03a ....TTIPTL HREHPEPETL TTAL....AT ..LHTTGHTT T....... atnid02a ....TTIPTL HREHPEPETL TTAL....AT ..LHTTGHTT T...... ....TTIPTL HRERPEPETL TQAI....AA VGVRTDGIDW A..... atnid00a atfkb10a ......AVL RARTGEES.. ....AALTAV AELHAHG.AP V..DL.AAVL atrap14a .....AVL RPRSPEDV.. ....CLMTAI AELHAGG.TA I..DW.AKVL atmon06a ....VLVASL AGERPEES.. ....AFVEAM ARLHTAG.VA V..DW.SVLF atmon08a ....VLVSSL AGERPEES.. ....AFVEAM ARLHTAG.VA V..DW.SVLF atmon09a ....VVTASL HPDRPDDV.. ....AFAHAM ADLHVAG.IS V..DW.SAYF atepo02a ....TLLASL RAGREEA... ...AGVLEAL GRLWAAGGS. V..SW.PGVF atepo03x ....TLLASL RAGREEA... ... AGVLEAL GRLWAAGGS. V..SW.PGVF ....VLLPAS RAGRDEA... ...ASALEAL GGFWVVGGS. V..TW.SGVF atepo08a ....ALLASS RAGRDEP... ...ATVLEAL GGLWAVGGL. V..SW.AGLF atepo00a ....VLVPSL RADRSEC... ...EVVLAAL GAWYAWGGA. L..DW.KGVF atepo04a AFAAALRRGR ....PEC... ...ATVLPAA ATAFVQG.AH V..DW.AAPY atnid07a LLPAIHKPGT APHGPAA... ... PGALRAA AAAYGRG.AR V..DW.AGMH atty107a PCAFL..PTL RKGRDDA... ... EAFTAAL GALHAAG.LT P..DW.SAFF atsor02a atsorbla PCAFL..PTL RKGRDDA... ... EAFTAAL GALHAAG.LT P..DW.NAFF .AVTL..PAL RAGRPEE... ...HTLTTAL AGLHVHG.AT L..DW.TGCF atnys09a .AL.L..PTL RGDRPEE... ...PALVTAV AAAHAHG.AR V..DW.SGYF atnys12a .L.VT..PTL RKDRDEE... ...SALLAGL ARLHVAG.VT V..DW.SAAL atnys16a .E.VV..PAL RKGRPEE... ...HTALTAA AQLHVAG.VD I..DW.TAVL atnys17a .A.AV..PLL RKDRPEE.....LSAVTGL ARAHVRG.VT V..RW.AGLF atnys03a .V.SV..PVL RKDRDEE... ... PAAVAAL ARLHTAG.VP V..DW.TAFY atnvs15a .L.AV..PLL RKDRPEE... ...PAALAAL AQLHIAG.AR V..DW.PVLF atnys07a .V.TV..PVL RKDRGEE... ...STALTAR AHLHTRG.LI E..DW.QDFF atnys08a atnys05a .A.TV..PAL RKDRDEE... ...TSALTAL AHLHTAG.LR V..DW.AAFF .V.TV..PVL RRNMPEE... ...RTLLTAL GRLHTTG.TP I..DW.AALL atnys06a .G.TI..PLL RRDRPEE... ...QAVLAAL CHLQVLG.VE A..DW.SATF atnvs04a .V.VV..PAL RRNRDED... ...ETLVGAV ARLHVHG.AG P..RW.DAYF atnys14a .TDVV..PAL SKGRPEE... ... TAFAGAL GRLHTLG.VP V..DW.PAFY atnys00a .AELV..PML RAGRAEE.....LAAATAL ARLQVRG.VD V..DW.AAYL atnys10a .LVAV..PVL RKERPEE... ...TTVLAAL GTLWAHG.AD V..DW.DAVF atnys18a PAVVV..PLQ RRDRAGD... ...LALLEGL ATLHTHG.TG P..SW.PAYF atnys13a .ARAI..PAL RPDQPEA... ...RSVMTAL AELFVAG.TA V..EW.AGVF atave10a ....V..ATL RKNGAEV... ...PDVLTAL AELHVRG.VG V..DW.TTVL atrif02a atmon03a EPEPVVAAAL RSKHDEG.....RTLLGAV AALHTDG.QP A..DL.TALF atavel2a PQENLLIPLL RPDSPEP......GTLLTGL ARLHTHGAAA V..NW.PAAL .AEVTCVAAL RDDRPEV.....TALITAV AELFVRG.VA V..DW.PALL atrif09a ....AAIATC RRGRDEV... ...ATFLRSL AQAYVRG.AD V..DF.TRAY atmon00a PDPLLTLPLL RRSVPETGDA EHPGGFERAL ATAYAHGV......PLRL atty103a

Fig 2t

		22	/26		
	501		-		550
atave00x		VRAHTMAVLN		~~~~~~	~~~~~~
atdebs00p	GSLPE.FAPA		VDWNAPPHVL		~~~~~~
atepo06p		RRVPLPTYPW	QHERCWIEVE	PDARR~~~~	~~~~~~~
atepo07p		RRVPLPTYPW	QHERYWIEDS	VHGSKPSLRL	
atepo01p		RRVPLPTYPW		AKSAAGDRRG	
atepo05p		RRVPLPTYPW	QRERYWVDAP	TGGAAGGSRF	
atsoralx		ESMPLPSTAG	~~~~~~~	~~~~~~~	~~~~~~
atfkb01p	Р.Н		DHKRYWLQPA	PVT~~~~~	mpms up
atfkb09p		RLLDLPTYPF	DHKRYWIEAT	GAADLTALGL	TDTAHP~~~~
atrap03p	TTT		QHQRYWVE	.GVDRSAAG.	GHPLLGV
atrap06p		RVLDLPTYAF		.SVDRAAAD.	GHPLLGT
atrap04p		RVLDLPTYAF		.SVDRAAAD.	GHPLLGT
atrap13p		RVLDLPTYAF RVLDLPTYAF	QHQRYWLK	.GVDRAAAD.	GHPLLGT
atrap01p		RVPDLPTYAF		.GADRSVAG.	GHPLLGV
atrap07p atrap10p		RVLDLPTYAF	OHORYWAEAG	RSADVSAAGL	
atfkb04x		TAHDLPTYAF		TGTDASGLGL	
attyl04p		HLTTLPTYPF	NHHHYWLDTT	PTTPA.TTTQ	
atty104p atty106p		HLTTLPTYPF	NHHHYWLDTT	PTTPA.TTTQ	
attyl01p		HLTTLPTYPF		PTTPA.TTTQ	
atty102p		HLTTLPTYPF	NHHHYWAVTS	PAGVG.DAA.	
attyl00p		HLTTLPTYPF	NHHHYWLDTI	DGGGGDDATQ	
atnid05b		RPVELPTYPF	ORERYWCHP.	GVRGGDPASL	
atty105b		RRVNPPTYPF	ORERYWYHPT	SGRRGDITAA	
atnid06x		RRVPLPSYAF	HRDRFWLPTA		~~~~~~~
atdebs01p		RRVPLPTYPF	QRERVWLEPK	PVARRSTEVD	EV~~~~~~
atmon02p		RTIDLPTYAF	QRRRYWLADT	VKRDSGWDPA	GS~~~~~~
atmon10p		RTVDLPTYAF	QHQHYWLERS	ASASGAVSGE	QSA~~~~~
atmon04p	PADPTP	RTVDLPTYAF	<b>QHQHYWLEEP</b>	SGLTGDAADL	GMVA~~~~~
atmon07p	PADPTP	RTIDLPTYAF	QRRSYWLP	VDGVGDVRSA	
atmon11p	PADPTP	RTVDLPTYAF	<b>QHKHYWVEPP</b>	AAVAAVGGGH	
atmon12p	PAVPLP	RVVDLPTYAF	QRERFWLEGR	${\tt RGLAGDPAGL}$	GL~~~~~
atmon05b	PADPAP	RTVDLPTYAF	QRQDFWPAPA	${\tt GGRSGDPAGL}$	GLAASGHP~~
atmon01p	PATGT.		QRRRYWLEAP	${\tt TG.TQDAAGL}$	GL~~~~~
atdebs02p		GLVDLPGYPF	QGKRFWLLPD	RTTPRDEL.D	
atdebs06p		PPVALPNYPF	EPQRYWLAPE	VSDQLAD	
atave01p		THLDLPTYPF	QHQHYWLESS	QPGAGSGSG~	
atave07p	THHHTHPHNH	.HLDLPTYPF		PTGAGDV~~~	T M D M M M D T
atave06p		THLDLPTYPF	QHQHYWLQPP	TTTTDLTTTG	LTPTHHPL~~
atave09p	ТОТНРИРНИН	.HLDLPTYPF	QHQHYWLQ~~		
atnys01p	EGTGA	ARVDLPTYAF	QRERIW.NIR	TAAUKIPAUA	EMPWEE AWA
atnys11p	EGTGA	SRIDLPTYAF .RVELPTYAF	OUCHEM TO	PAPEAVAAAD	I.GI.ACADHDI.
atrif05p	PPA	.RVDLPTYAF	DUOUPW ID	DANCA DAUG	T.CODARRHOT.
atrif07p	ATT	.RVDLPTYAF	DUÕULMTV	VURTATION	accases a
atrif08p		.RADLPTYAF			
atrif10p atrif03p	האת האת	GWVDLPTYAF	DDDUEW T.H	FARTARARG	M~~~~~~
-	חממ	GRVDLPKYAF	DUDUVW T.D	DAFCATDAAC	T.GOGAADHPT.
atrif06p atrif04p	DDQ	RRVELPTYAF	DHOHAM TO	MCCSATDAV~	~~~~~~
		GWVDLPTYAF	EHDHVW T.E	DAEDASAGDD	LLGT~~~~~
atrif01p atnys02p	A DCDV	QPVDLPTYPF	ORODEWPEAR	PATPAAGADA	SD~~~~~
athysuzp atfkb02p	p PCRT.	RGVPLPTYPF	BEDEAMAUDE	PAGTSGHP~~	~~~~~~~
atikb02p atave11p	GSAGBGAAGG	CGVELPTYAF	EREREWLDVE	GAPRGSGVSG	OW~~~~~
atdebs03p	PGA	APFALPTYPF	ORKRYWI.OPA	APAAASDELA	YRV~~~~~
atnid04p	PRA	GWVDLPTYAF	ORERYWVAPA	EPGPAAGAGS	AAATGPAAA~
atdebs05p	ANA	RPVELPVYPF	ORORYWI.PTP	TGGRARDEDD	DWR~~~~~
atdebs04p	RPAVAGG	RPAELPTYPF	EHORFWPRPH	RPADVSALGV	R~~~~~~

Fig 2u

### 23/26

			•		•
		f	=ig2v		
46034034		****			•
atmonuua attyl03a	APAPDAASLA	VAAELPTYA	F QRTHYWLDA	P AAPAALPAG	L DDAGHPLLSA
atrii09a atmon00a	CDT	RREPLETYP	F ORERHWPAA	A GVGQQ.PET	5 FP5~~~~~
atave12a atrif09a	PDMACE	VDT.PKYA	F DOOHYWLOP.	A AOATD AASI	L GQV~~~~~~
atmon03a	YADA	GUVELETIK	E DHHBAMADA E ÄVVVIMVAY	S AGHPG. DIS	A AGLGT~~~~
atrif02a	DEPATA	ACTATE DUMANT	E ODDDAMDUY.	DAAAD ARAA	A GLQ~~~~~
atave10a	EGTAREVGDG	CGVELPTYA	E CRUBERTON	5 EGUAG.GUG 7 ET~~~~~~	/ SGMWGGPLWE
atnys13a	EATGG	HRTDLPTYA	P QRERYWPEL	FEGUE COCT	PAAW~~~~~
atnys18a	AGTRTPQA	DPVELPTYAL	P QRARYWPTL	AKHGU.PADI	G~~~~~~~
atnys10a	ΔCT GA	RRTDLPTYAI	OHAYYWPO.	LPTPA AALA	Y AWDAWDÖÖLM
atnys00a	ΔGTGA	RRVELPTYAL	OHVRHWPT.	, PPRPN.GAGE	GALGHPLLG~
atnys14a	ACD GA	OWIDIPTYPE	ORGREWPE.	SLPGA.ASAA	PAAGQPA~~~
atnys04a	RGLDP	VRVDLPTYA	CHRWFWPA.	ARPAR.PDDV	RAAGLGAA~~
atnys06a	APTGA	RPVDLPTYAL	CHRPFWPS.	GPRDTADA	AAVGIAGASH
atnys05a	AGSGA	TRVDLPTYA	QHATYWPT	GTLPTAHA	AAVGL~~~~
atnys08a	AGVGA	GRVELPTYA	QRGWFWPV	GRVGV.GGDV	GAVGLGSAGH
atnys07a	AGVGA	GRVELPTYA	QRGWFWPV	GRVGV.GGDV	
atnys15a	AGTGA	HRTDLPTYAE	QYERYWPK	ATY.R.PADA	TGL~~~~~
atnys03a	DGTGA	RRADLPTYPE	QHQRFWPT	AAR.A.AQDV	TAAGLGAADH
atnys17a	AGTGG	RRIALPTYAF	QRERYWPS	LAAQA.PGDA	GG~~~~~~
atnys12a	TGTGA	RGTDLPTYAF	' QRERYWPE	LAAEP.AG	GGADAADA~~
atnys03a	ADHGA	RRTTLPTYAF	' QRERYWPDT'I	AATSA.HTPG	SALDAREW
atnys09a	7 CT C7	DDTOT.DTYAF	ORRRYWPKAL	OSGTA. DLKS	AGTICAV
atsorbla	ל איז מי	CUTTOT DOVER	~~~~~~~	~~~~~~~	
attyru/a atsor02a					
athidu7a atty107a					
atepou4a atnid07a		かいいいて ひかびひだ		~~~~~~~~	~~~~~~~
atepouua atepo04a	מסכת	DOWNT. DMVDW	OPERHMMDI-T	PRSAA PAGI	ACKMPLAGVG
atepouda atepo00a	PSCC	PRVPLPTYPW	ORERYWIDTK	ADDAA.RGDR	KAPGAGRUEV
atepo03x atepo08a	PSCC	PRVPI.PTYPW	ORERYWIEAP	VDREA.DGTG	~~~~~~~
atepo02a	ውሞአር	DDWDI.DTYDW	ORORYWPDIE	PDSRR.HAAA	DPTQGWFI~~
atmon09a	ን ለጥብ	DOVIDI, DTYPW	ORORYWIEAP	AE~~~~~~	~~~~~~
atmon08a	AGDRVPGL PDDPAPRT	VDT.PTYAF	OGRRFWLADI	AAPEAVSSTD	GEEA~~~~~
atmon06a		VEL PTYAF	ORERFWLSG.	RSGGGDAATL	GLVAAGHPL~
atrap14a		ALLA DITE A TEL	ORERFWISG	RSGGDAATL	GLVAAG~~~~
atfkb10a	AGG	DYADI'DAADE VEADTEATER	OHOSYWIAPA	APDATAVA	PVVEEEGGEY
atnid00a	VLCGASKP	VKADTEITYL VKADTEITYL	OHRSYWT.APA	VGGGSPTAVP	D~~~~~~
atnid02a	PHPSHIPA	OKASTEWIEL	ORRTHWAPCT.	TPNHAPADRP	AAEPORAMAV
atnid03a	LHTTSPQS	WWTDPLITL	OBBZAMM D	PPRAAVGDLA NSAAHIGRSD	AEAATRLGLA
atnid01a	LHTTSPQT	HHLDLPTYPF	ORDRAMM'EL	VRVAQVSGQP	GWDUTIVITY A
atfkb08x	GGASRHDP	DVPSYAF	QRRPYWIE.S	APPATADSG.	
atfkb07x	.GSDRAPV	ALPTYPF	QHKDYWLRAT	AQVDVTGAGQ	HPVLGT
atfkb03a	GAAP.TDL	PHLPTYPF	ERTRYWLGSR	AAGDA~~~~	
atrap09a	GDVPVTRV	LDLPTYAF	QQQRYWAEVG	RSADVSGAGL	DAVGHPLLGA
atrap05a	GDAPATRV	LDLPTYAF	QHQRYWLE	.GADRAAAG.	GHPLLGP
atrap12a		LDLPTYAF	QHQRYWLE	.GTDRATAG.	GHPLLGS
atrap08a	GDAPATRV	LDLPTYAF	QHQRYWLE	.GTDRMAAG.	GHPLLGE
atrap11a	GDVPVTRV	LDLPTYAF	QHQRYWLE	.GTDRATAG.	GHPLLGS
atrap02a		LDLPTYAF	QHQRYWLE	.GTDRATAG.	GHPLLGS
atave03a	THHHNQPHTH	THLDLPTYPF	QHHHYWLQ		SP~~~~~
atave08a	THHHNQPHTH '	THLDLPTYPF	QHHHYWLE	STOPGAGNVS	AA~~~~~
atave04a	THHHNOPHTH '	THLDLPTYPF	QHQHYWLE	STOPGAGSGS	GSGSGRAG~~
atave05a	THHHNQPHTH !	THLDLPTYPF	OHHHYWLELP	SAOTSPGQRR	SRRSAPD~~~
atave02a	THHDNQPHTH !	THLDLPTYPF	OHHHYWLE	STQPGAGNV~	~~~~~~

LPTY motif




Fig3

Erythromycin D

Erythromycin A

Erythromycin C

PCT/GB01/03642

	1	
  -  - 		17360
17359	_	17300
17299	_	17240
17239	_	17180
17179		17120
17119	CCICCICGGCCIGGICACCAAGCACGIGGCCGICGIGCICGGGGACGCCICGGGCACGGI	17060
17059	_	17000
16999	•	16940
16939	CCAGCGCGAGCGCCATTGGCCTGCCGCTGCCGGGTGGGGCAGCAGCCGGAGACCCCGGA	16880
16879	CITCACCCGGCCTACGCGCCACCGCCACGCGCCGCTTCCCCCTCCCCACGTATCCCTT	16820
16819	CGAGGTGGCCACGTTCCTGAGGTCGCTGGCCCAGGCGTACGTCCGCGGCGCCCGATGTCGA	16760
16759	CCCCGCGGACCGGAGCCGTCCGCCCCCCCCCCATCGCCACATGCCGCCGCGGGGGGGG	16700
16699	GITÉGICGAGCICGGCCCGGACGCACCGCIGICCGCGAIGGCCCGCGACIGCTICCCCGC	16640
16639	GCGCGAGCCCGTGCGGTTCCTGTCCGGGGTGCGGGGGCTGTGCGAGCGCGGGGTGACCAC	16580
16579	CGCGACCGCGACCGGGGGGCGCCGGGCAGGCCCGGAGTACTGGGCGCGCGC	16520
16519	CCTGACCTTCCACGAGCCGGTCATTCCCGTCGTCTCCAACGTCACCGGTGAACTGGTGAC	16460
16459	CGCCTTCCACTCCCCGCACATGGACCCCATCCTCGACGAGCTGCGCGGGTCGCCGGG	16400
16399	CGAACTGACCGCCCTGGCGGGGGCGGCCGCAAGGCCCCACCTGAAGGTCAGCCA	16340
16339	CETGGCCGCCGTCAACGCCCCCGACTCCGTGGTCGTCTCCGGCGACCGCGCCACCGTCGA	16280
16279	GIGGCAGGCCACGGCGGAGGCGGCCGAACAGCICGCCGGGCACGAGGGGCACGTCAC	16220
16219	TCTGGTGGCCACGCGGGGACGCCTCATGCAGGCGGTTCGCGCGCCCGGCGCGATGGCCGC	16160
16159	GGTCGGCGAGATCGCCGCGCGCACGTCGCCGGTGTCCTCTCGTTGCCGGACGCGAGCGC	16100
16099	GAGCCTGTACCGGCTGCCAGCCTCCTTCGGCCTGAAGCCGGACTACGTCCTCGGCCACTC	16040
16039	CCATCAGGCACTCCTCGACCAGACCGCCTACACCCCAGCCCGCGCTCTTCGCGATCGAGAC	15980
15979	GGGCGAGACCGGTCGGGTGGGAACGTCTCGGGTGAGAATGTCATCGGCGAGGGTGCCGA	15920
15919	CGACGAGGCGTTCGCCGCCCTGGACGTACATCTGGACCGCCCACTGCGCGAGATCGTCTT	15860
15859	_	15800
15799	CGTGCGCGCGCGAGGCGTACACCGAGGCAGGACGGCCTTCCTCTTCAGTGGGCAGGGAGC	15740
15739	CACCGCCGAACTGCTGGGCTCCCTGGACGCGCTGGCCGAGGGCGCGGAGACCGCGTCCAT	15680
15679	CCACGCGCTCGCCACCACCGCGCCCCTCGCCCACCGCGCGGGTCCTGCTCGGCGGCGA	15620
15619	_	15560
15559	GGTGGTGCCGACGCCATGGCCCCGTGAGCGCTCACAGCGCTTCCGCGCTGCGCGCGC	15500